

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 955 364 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
10.11.1999 Bulletin 1999/45

(51) Int. Cl.<sup>6</sup>: **C12N 15/12**, C12N 15/10,  
C12N 15/90, C07K 14/435

(21) Application number: 98309554.8

(22) Date of filing: 23.11.1998

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: 27.04.1998 US 67755

(71) Applicant:  
**INSTITUTE FOR MOLECULAR BIOLOGY AND  
BIOTECHNOLOGY/FORTH  
GR-711 10 Heraklion (GR)**

(72) Inventors:  
• **Savakis, Charalambos**  
**Heraklion 700 13, Crete (GR)**

• **Franz, Gerald H.**  
**2500 Baden (AT)**  
• **Loukeris, Athanasios**  
**Heidelberg (DE)**  
• **Klinakis, Apostolos G.**  
**71500 Gazi, Heraklion (Crete) (GR)**

(74) Representative:  
**Price, Vincent Andrew et al**  
**FRY HEATH & SPENCE**  
**The Old College**  
**53 High Street**  
**Horley Surrey RH6 7BN (GB)**

(54) **Eukaryotic transposable element**

(57) Disclosed are isolated transposable elements, isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein), a purified transposase protein, or peptide fragments thereof, encoded by the DNA sequences. The isolated transposable elements and the isolated DNA sequences are characterized by the ability to hybridize to the DNA sequence of Minos-1. Further disclosed are methods of gene tagging, insertional mutagenesis and exon trapping. Transgenic animals and transgenic plants are also disclosed.

**EP 0 955 364 A2**

## Description

## BACKGROUND OF THE INVENTION

[0001] The Tc1-like family of transposons and the retroviral-like transposons are unique for their wide dispersion in diverse organisms. Members belonging to the Tc-1-like family have been characterized in nematodes, diptera, fish and amphibians: Tc1 in *Caenorhabditis elegans*, Tcb1 in *Caenorhabditis briggsae*, HB1 in *Drosophila melanogaster*, Uhu in *Drosophila heteroneura*, Minos in *Drosophila hydei*, and Tes1 in the Pacific hagfish *Eptatetrus stouti*. All are characterized by a relative short length (1.6 to 1.8 kb), the presence of inverted terminal repeats, and significant sequence similarity in the region between the repeats.

[0002] The Minos-1 transposable element has been identified as a 1775 bp dispersed repetitive sequence inserted within the transcribed spacer in one of the repeats of *Drosophila hydei* (Franz and Savakis, *Nucl. Acids Res.* 19: 6646 (December 11, 1991)). The element is characterized by 255-bp long perfect inverted repeats and the presence of two long, non-overlapping open reading frames (ORFs) on the same strand. The longest of the ORFs shows approximately 30% sequence identity with TcA, but does not begin with an ATG codon. It appears, therefore, that the cloned element represents a defective member of the Minos family, as is the case with all previously sequenced Tc1-like elements, with the possible exceptions of Tc1 and Tcb1.

[0003] Transposable elements are natural components of genomes ranging from bacteria to vertebrate organisms (Lewin, *Genes VI*, Chapter 18, Oxford University Press, (1997)). Thus, due to their widespread phylogenetic distribution, evolutionary conservation and genomic mobility, transposons are valuable tools for genetic manipulations, such as, for example, the integration of nucleic acids in germ cells for the production of transgenic animals, and genetic transformation and insertional mutagenesis in somatic cells and viral vectors for use as therapeutics.

## SUMMARY OF THE INVENTION

[0004] The invention relates to an isolated transposable element, or an isolated DNA sequence which encodes a transposase protein (or a portion of a transposase protein), to a purified transposase protein, or peptide fragments thereof, encoded by such a DNA sequence, and to methods of using the transposable element and transposase protein. The isolated transposable element and the isolated DNA sequence are characterized by the ability to hybridize to the DNA sequence of Minos-1 under stringent hybridization conditions.

[0005] In another aspect, the invention relates to a method for the stable introduction of a nucleic acid sequence of interest into a cell. This method involves the use of an isolated transposable element of the type described in the preceding paragraph, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the termini of the isolated transposable element. This modified transposable element is introduced into the cell in the presence of a transposase protein, or a nucleic acid sequence or a virus encoding a transposase protein. The role of the transposase protein is to catalyze the transposition of the modified transposable element containing the nucleic acid sequence of interest into the genome of the cell. Also envisioned are cells produced by this method.

[0006] In a third aspect, the invention relates to a method for isolating members of the Tc-1 family of transposable elements from genomic DNA of a eukaryote of interest. According to this method, oligonucleotide primers are provided which are complementary to a sequence of at least about 12 consecutive nucleotides which encode amino acids which are highly conserved in aligned sequences of nematode Tc-1 family members and Minos family members. These oligonucleotide primers are used to prime amplification by the polymerase chain reaction (PCR). The amplification products are then used to isolate DNA encoding the entire Tc-1 family member from the eukaryote of interest by conventional methods.

[0007] In a fourth aspect, the invention relates to a transgenic animal, which is produced by a method which involves the use of an isolated transposable element characterized by the ability to hybridize to the DNA sequence of Minos-1, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the termini of the isolated transposable element. This modified transposable element is introduced into a cell in the presence of a transposase protein, or a DNA sequence or a virus encoding a transposase protein.

[0008] In a fifth aspect, the invention relates to methods of integrating a nucleic acid sequence of interest into a chromosome of a cell. This method involves the use of an isolated transposable element of the type described in the preceding paragraph, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the termini of the isolated transposable element. This modified transposable element is introduced into the cell in the presence of a transposase protein, or a nucleic acid sequence or a virus encoding a transposase protein. Also envisioned are cells produced by this method.

[0009] In a sixth aspect, the invention relates to a transgenic plant, which is produced by a method which involves the use of an isolated transposable element characterized by the ability to hybridize to the DNA sequence of Minos-1, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the termini of

the isolated transposable element. This modified transposable element is introduced into a plant cell in the presence of a transposase protein, or a nucleic acid sequence or a virus encoding a transposase protein.

[0010] In a seventh aspect, the invention relates to insertional mutagenesis and gene tagging. In this approach, the Minos-transposable elements are inserted into a nucleic acid (e.g., a gene) to induce a mutation in the nucleic acid which produces a phenotypic alteration. The location of the nucleic acid is identified by the presence of the Minos transposon sequence. The Minos transposon sequence can be identified, for example, using standard molecular hybridization techniques, such as *in situ* hybridization, Southern blotting, and colony hybridization. The terms "transposable element" and "transposon" are used interchangeably herein.

[0011] In a particular embodiment, this aspect of the invention relates to methods for inducing a mutation of interest in a cell (a Minos transposon-induced mutation), and identifying and isolating a gene of interest which includes the mutation from the cell. The methods involve the use of an isolated transposable element of the type described above which is introduced into a cell in the presence of a transposase protein, or a nucleic acid sequence or a virus encoding the transposase protein. In a particular embodiment, the transposable element is modified to include a promoter operably linked to an indicator gene (such as a reporter gene or a selectable marker gene) flanked by the inverted terminal repeats of the isolated transposable element. In a further embodiment, expression of the indicator gene is detected, thereby identifying cells in which the transposable element has integrated into the genome of the cells. Cells which have a mutation of interest can then be identified and selected by looking for a particular phenotype conferred by the mutation but not the corresponding endogenous gene. These cells are referred to herein as cells including a Minos transposon-induced (or Minos transposable element-induced) mutation. The location of the gene which includes the mutation can then be identified by the presence of the Minos transposon sequence and then isolated.

[0012] In a second embodiment, this aspect of the invention relates to methods for selecting an insertional mutation in a gene (a Minos transposon-induced mutation). The methods comprise introducing a transposable element of the type described above, modified to include a minimal promoter or a splice acceptor site operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element, into a population of cells in the presence of a transposase protein, or a nucleic acid sequence or a virus encoding the transposase protein. Expression of the indicator gene is detected, thereby identifying cells in which the transposable element has integrated near or within a particular gene in the cells. These cells are also referred to herein as cells including a Minos transposon-induced (or Minos transposable element-induced) mutation. The location of the gene in which the transposable element has integrated near or within is identified by the presence of the Minos transposon sequence and then isolated.

[0013] In an eighth aspect, the invention relates to methods for reversing a Minos transposon-induced mutation in a cell. The methods comprise introducing a transposase protein, or a nucleic acid sequence or a virus encoding a transposase protein, into cells identified as including a Minos transposon-induced mutation, as described herein. The transposase protein catalyzes reversion of the Minos transposon-induced mutation. Cells in which reversion of the mutation has occurred can be identified, for example, by looking for loss of a particular phenotype conferred by the mutation or for absence of the product encoded by the indicator gene.

[0014] In a ninth aspect, the invention relates to a method for introducing a reversible mutation in a gene of interest in a cell. In a particular embodiment, this method involves the use of a Minos transposable element modified to include a promoter operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element. In a second embodiment, this method involves the use of a Minos transposable element modified to include a minimal promoter operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element. In a third embodiment, the method involves the use of a Minos transposable element modified to include a splice acceptor site operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element. The modified transposable element is introduced into a gene of interest, thereby producing a mutated gene. The mutated gene is introduced into a sample of cells under conditions sufficient for homologous recombination between the mutated gene and the endogenous gene. Thus, in this aspect of the invention, the gene of interest is a gene which has sufficient sequence homology to the endogenous gene in which a reversible mutation is to be introduced, for homologous recombination between the endogenous gene and the mutated gene. Cells in which the endogenous gene has been replaced with the mutated gene can then be identified and selected by looking for a particular phenotype conferred by the mutated gene, for loss of a particular phenotype conferred by the endogenous gene or for presence of a product encoded by the indicator gene. The mutation in the gene introduced in accordance with the present method can be reversed by a method comprising introducing a transposase protein, or a nucleic acid sequence or a virus encoding a transposase protein, into cells in which the endogenous gene has been replaced with the mutated gene. Cells in which reversion of the mutation has occurred can be identified, for example, by looking for loss of a particular phenotype conferred by the mutated gene, for a particular phenotype conferred by the endogenous gene or for absence of the product encoded by the indicator gene.

[0015] In a tenth aspect, the invention relates to a method for inducing loss of a nucleic acid sequence of interest integrated into the chromosome of a cell. In a particular embodiment, the nucleic acid sequence of interest refers to a gene of interest. The method comprises introducing a transposase protein, or a nucleic acid sequence or a virus encoding a

transposase protein, into cells identified as including a nucleic acid sequence of interest which was integrated into the chromosome of a cell using an isolated Minos transposable element of the type described above. Cells in which loss of the nucleic acid sequence of interest has occurred can be identified, for example, by looking for loss of a particular phenotype conferred by the nucleic acid sequence of interest or for absence of the product encoded by an indicator gene.

## BRIEF DESCRIPTION OF THE DRAWINGS

### [0016]

Figure 1A-1C is a diagram providing the consensus sequence of elements Minos-1, Minos-2 and Minos-3 with nucleotide deletions after nucleotides 365, 678 and 715. The terminal inverted repeats and the intron sequence are shown in small letters. Differences between the three elements are indicated above and below the nucleotide sequence. More specifically, nucleotide 896 is a G in Minos-2 and Minos-3 and an A in Minos-1. Nucleotide 1157 is a C in Minos-1 and Minos-3 and a T in Minos-2.

Figure 2A-2C is a diagram providing the consensus sequence of elements Minos-1, Minos-2 and Minos-3. The terminal inverted repeats and the intron sequence are shown in small letters. The first and last nucleotides of the sequence, A and T, respectively, are generated by a duplication of the chromosomal target site TA during insertion of the element. The deduced amino acid sequence of two open reading frames is shown above the nucleotide sequence. Differences between the three elements are indicated above and below the nucleotide sequence. More specifically, nucleotide 900 is a G in Minos-2 and Minos-3 and an A in Minos-1. Nucleotide 1161 is a C in Minos-1 and Minos-3 and a T in Minos-2. Amino acid residue 148 is a tryptophan in Minos-2 and Minos-3 and a stop codon in Minos-1. Amino acid residue 235 is a serine in Minos-1 and Minos-3 and a leucine in Minos-2.

Figure 3A is a diagram of the insert of the transposon plasmid pMihsCcw. ML and MR signify the left- and right-end parts of *Minos*, respectively. Speckled boxes indicate the *D. melanogaster* Hsp70 promoter (Hsp70-P) and terminator (Hsp70-T) sequences. Wide hatched bars indicate the *Minos* (M) and *Medfly white* (W) sequences that were used as probes for the analysis of transformants.

Figure 3B is a diagram of the insert of the *Minos* helper plasmid pHSS6hsMi. Speckled box indicates the *D. melanogaster* Hsp70 promoter (Hsp70-P) sequence. Salient restriction sites are shown. Exon 1 and exon 2 are also referred to herein as open reading frame 1 (ORF1) and open reading frame 2 (ORF2), respectively. IR indicates the right-hand terminal inverted repeat.

Figure 4 is a bar graph depicting the frequencies of transformants among G1 progeny. Bars indicate the numbers of G1 flies from the individual cages. The sex of the G0 flies in each cage is indicated. The numbers above cages 1, 3, 25 and 33 indicate the w<sup>+</sup> flies that were recovered from these cages.

Figure 5 is a diagram of the helper plasmid pEF1/ILMi. The arrow represents the transcription start site and indicates the direction of transcription of the *Minos* (Mi) transposase gene which is linked to the human translation elongation factor (EF1)-promoter. The fragment containing the EF1 promoter also comprises a 943 bp intron in the 5' untranslated region which provides an intron for the transposase RNA transcript. Upstream from the EF-1 promoter is the SV40 origin of replication (ori). The 3' end of the *Minos* transposase gene contains a polyadenylation signal from the human granulocyte colony-stimulating factor gene (hG-CSF).

Figure 6 is a diagram of the transposon plasmid pMiLRneo. The arrowhead represents the transcription start site and indicates the direction of transcription. The plasmid contains the neomycin (neo) resistance gene under the control of the early SV40 promoter, flanked by two inverted repeats of the *Minos* transposable element (bolded arrows).

Figure 7 is a diagram of the plasmid pMiLneo. The arrowhead represents the transcription start site and indicates the direction of transcription. The pMiLneo plasmid is derived from pMiLRneo (Figure 6) by deletion of the right hand repeat of *Minos* to generate the defective transposon "wings clipped". The remaining left hand inverted repeat is indicated by the bolded arrow.

## SEQUENCE LISTING CROSS-REFERENCE

[0017] In portions of the Specification, the following sequence listing cross-reference is applicable:

SEQ ID NO: 1 Nucleic acid sequence of Minos-1 with nucleotide deletions after nucleotides 365, 678 and 715.  
 SEQ ID NO: 2 Nucleic acid sequence of Minos-2 with nucleotide deletions after nucleotides 365, 678 and 715.  
 SEQ ID NO: 3 Nucleic acid sequence of Minos-3 with nucleotide deletions after nucleotides 365, 678 and 715.  
 SEQ ID NO: 4 Nucleic acid sequence of Minos-1.  
 SEQ ID NO: 5 Deduced amino acid sequence of Minos-1.  
 SEQ ID NO: 6 Nucleic acid sequence of Minos-2.

SEQ ID NO: 7 Deduced amino acid sequence of Minos-2.

SEQ ID NO: 8 Nucleic acid sequence of Minos-3.

SEQ ID NO: 9 Deduced amino acid sequence of Minos-3.

SEQ ID NO: 10 MVWGC.

5 SEQ ID NO: 11 WPSQSPDL.

SEQ ID NO: 12 WPSNSPDL.

#### DETAILED DESCRIPTION OF THE INVENTION

10 [0018] The invention disclosed herein is based on the initial discovery of Minos-1, an apparently defective member of the Tc-1 family of transposable elements. This 1779-hp element is characterized by perfect inverted repeats of 255-bp at each termini. The sequence encodes two non-overlapping reading frames, one of which has significant similarity with the putative transposase encoded by the transposable element Tc1 of *Caenorhabditis elegans*. However, the Minos-1 element, because of a stop codon within the putative transposase gene, apparently cannot encode an active transposase.

15 [0019] In an effort to identify sequences related to the Minos-1 sequence, genomic DNA of *D. hydei* was probed with a portion of the Minos-1 sequence under stringent hybridization conditions. As discussed in detail in the Examples section which follows, two full-length related sequences were identified, both of which encode an active transposase.

#### 20 ISOLATED NUCLEIC ACIDS AND USES THEREOF

[0020] Thus, in one aspect, the subject invention relates to an isolated transposable element which hybridizes to the DNA sequence of Minos-1 under stringent hybridization conditions. As used herein, stringent hybridization conditions are considered to be hybridization in a buffered solution of 0.9 M NaCl at 55 °C. In *D. hydei* there are up to 30-copies detected which hybridize to Minos thus, it is likely that a large number of variants can be isolated using these conditions. Comparable hybridization stringency can be established at other salt concentrations and temperatures. This is accomplished, for example, by the inclusion of organic denaturants such as formamide in the hybridization buffer. Nucleic acid sequences which hybridize to the Minos-1 sequence under stringent hybridization conditions are referred to herein as members of the Minos family of transposable elements. Nucleic acid sequences which hybridize to the Minos-1 sequence under stringent hybridization conditions include, for example, the Minos-2 and Minos-3 DNA sequences. Other examples of nucleic acid sequences which hybridize to the Minos-1 sequence under stringent hybridization conditions include Minos-1, Minos-2 and Minos-3 DNA sequences having base deletions, insertions and/or substitutions.

[0021] The term transposable element, as used herein, refers to a DNA sequence whose excision from/insertion into genomic DNA is catalyzed by a functional transposase protein encoded by a non-defective member of the Minos family of transposable elements. A member of the Minos family which encodes a functional transposase and possesses other necessary cis-acting elements (e.g., inverted terminal repeats) falls within this definition. In addition, a transposable element which encodes a defective transposase (e.g., Minos-1 itself) falls within this definition. As discussed in greater detail below, such defective transposable elements can be used in conjunction with a helper element (e.g., a member of the Minos family which encodes a functional transposase) to introduce a nucleic acid sequence of interest into a cell (e.g., a eukaryotic cell such as an animal, plant or yeast cell or a prokaryotic cell such as a bacterial cell).

[0022] The invention also relates to an isolated DNA sequence encoding a functional transposase protein, or a portion of a transposase protein, encoded by a member of the Minos family. Such a DNA sequence need not retain the ability to transpose in the presence of the encoded transposase protein. A sequence encoding a functional transposase protein can be used to prepare an expression construct which can be used to produce the transposase protein by recombinant DNA methodology. Such a recombinant protein can be over-produced in a eukaryotic (e.g., yeast) or prokaryotic host cell (e.g., *E. coli*), and subsequently purified by conventional methods.

[0023] The active transposase can be used in a variety of ways. For example, as discussed below, the transposase can be co-introduced into a eukaryotic cell with a modified transposon carrying a nucleic acid sequence of interest to catalyze the insertion of the modified transposon into the genomic DNA of the eukaryotic cell. This is an alternative to the co-introduction of a helper construct in eukaryotic cells which do not constitutively produce the Minos transposase.

50 [0024] In addition, the transposase, or portions thereof, can be used to produce antibodies (monoclonal and polyclonal) reactive with the transposase protein. Methods for the production of monoclonal and polyclonal antibodies are straightforward once a purified antigen is available.

[0025] Through the isolation and DNA sequence analysis of additional members of the Minos family, refinement of the consensus sequence of Figure 2A-2C is possible. This refined consensus sequence can be used to predict modifications of the transposase protein which will affect the specific activity of the transposase. Such predictions are easily tested by modifying the DNA sequence of an expression construct encoding the transposase by site-directed mutagenesis to either bring the sequence into a greater degree of conformance with the consensus sequence, or a lesser

degree of conformance with the consensus sequence. The affect of such changes on the activity of the transposase protein are monitored by assessing the affect of the mutation on transposition frequency catalyzed by the recombinant transposase.

## 5 METHODS FOR THE INTRODUCTION OF NUCLEIC ACID SEQUENCES INTO A CELL

[0026] Transposable elements of the Minos family, and the active transposase encoded by such elements, are useful in methods for introducing a nucleic acid sequence of interest into a cell (e.g., a eukaryotic cell, such as an animal, plant or yeast cell or a prokaryotic cell, such as a bacterial cell). Typically, the nucleic acid sequence of interest will be a gene  
10 which encodes a protein. Such a gene can be placed under the regulatory control of a promoter which can be induced or repressed, thereby offering a greater degree of control with respect to the level of the protein in the cell. As used herein, the term "promoter" refers to a sequence of DNA, usually upstream (5') of the coding region of a structural gene, which controls the expression of the coding region by providing recognition and binding sites for RNA polymerase and other factors which may be required for initiation of transcription. The selection of the promoter will depend upon the  
15 nucleic acid sequence of interest. In addition to a nucleic acid sequence encoding a protein, any other nucleic acid sequence can be introduced by this method including, for example, regulatory sequences.

[0027] Nucleic acid sequences of interest are defined herein as heteropolymers of nucleic acid molecules. The nucleic acid molecules can be double stranded or single stranded and can be a deoxyribonucleotide (DNA) molecule, such as cDNA or genomic DNA, or an ribonucleotide (RNA) molecule. As such, the nucleic acid sequence of interest  
20 can, for example, include one or more exons, with or without, as appropriate, introns, as well as one or more of the following optional sequences, in a functional relationship: regulatory sequences (such as promoter sequences), signal or leader sequence, splice donor sites, splice acceptor sites, introns, 5' and 3' untranslated regions, polyadenylation sequences, and negative and/or positive selective markers.

[0028] In one example, the nucleic acid molecule contains a single open reading frame which encodes a protein. The nucleic acid of interest is operably linked to a suitable promoter. Optionally, the nucleic acid sequence can be operably  
25 linked to a reporter molecule.

[0029] The term "operably linked", as used herein, is defined to mean that the nucleotide sequences are linked to a regulatory sequence in a manner which allows expression of the nucleic acid sequence. In general, operably linked means contiguous.

[0030] Suitable promoters for use in prokaryotic and eukaryotic cells are well known in the art. Exemplary promoters include the SV40 and human elongation factor (EF1). Other suitable promoters are readily available in the art (see, e.g., Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York (1998); and Sambrook  
30 *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York (1989)).

[0031] Suitable promoters for use in plants are also well known in the art. For example, constitutive promoters for plant gene expression include the octopine synthase, nopaline synthase, or mannopine synthase promoters from *Agrobacterium*, the cauliflower mosaic virus (35S) promoter, the figwort mosaic virus (FMV) promoter, and the tobacco mosaic virus (TMV) promoter. Specific examples of regulated promoters in plants include the low temperature Kin1 and cor6.6 promoters (Wang, *et al.*, *Plant Mol. Biol.*, 28:605 (1995); and Wang, *et al.*, *Plant Mol. Biol.*, 28:619-634 (1995)), the ABA inducible promoter (Marcotte *et al.*, *Plant Cell*, 1:969-976 (1989)), heat shock promoters, and the cold inducible promoter from *B. napus* (White *et al.*, *Plant Physiol.*, 106:917 (1994)). Other suitable promoters are readily available  
40 in the art.

[0032] The term "reporter gene", as used herein, refers to a nucleic acid sequence whose product can be easily assayed, for example, colorimetrically as an enzymatic reaction product, such as the lacZ gene which encodes for  $\beta$ -galactosidase. The reporter gene can be operably linked to a suitable promoter which is optionally linked to a nucleic  
45 acid sequence of interest so that expression of the reporter gene can be used to assay integration of the transposon into the genome of a cell and thereby integration of the nucleic acid sequence of interest into the genome of the cell. Examples of widely-used reporter molecules include enzymes such as  $\beta$ -galactosidase,  $\beta$ -glucuronidase,  $\beta$ -glucosidase; luminescent molecules such as green fluorescent protein and firefly luciferase; and auxotrophic markers such as His3p and Ura3p. (See, e.g., Chapter 9 in Ausubel, F.M., *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York (1998)).

[0033] The generation of nucleic acid sequences and detection of reporter genes are standard molecular biological procedures well known in the art. Alternative combinations or modifications of the elements according to the present invention would be apparent to the person of skill in the art.

[0034] The nucleic acid sequences of interest can be isolated from nature, modified from native sequences or manufactured *de novo*, as described in, for example, Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998); and Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York (1989). The nucleic acids can be isolated and fused together by methods known in the art, such as exploiting and manufacturing compatible cloning or restriction sites.

[0035] The term "integrated", as used herein, refers to the insertion of a nucleic acid sequence (e.g., a DNA or RNA sequence) into the genome of a cell or virus as a region which is covalently linked on either side to the native sequences of the cell.

[0036] As used herein, a cell refers to a eukaryotic or prokaryotic cell. Typically, the eukaryotic cell is of animal or plant origin and can be a stem cell or somatic cell. The eukaryotic cell can also be a yeast cell, such as, for example, *Saccharomyces cerevisiae*. Suitable animal cells can be of, for example, invertebrate, mammalian or avian origin. Examples of mammalian cells include human (such as HeLa cells), bovine, ovine, porcine, murine (such as embryonic stem cells), rabbit, and monkey (such as COS1 cells) cells. The cell can be a fertilized egg cell, an embryonic cell, bone marrow stem cell or other progenitor cell. Where the cell is a somatic cell, the cell can be, for example, an epithelial cell, fibroblast, smooth muscle cell, blood cell (including a hematopoietic cell, red blood cell, T-cell, B-cell, etc.), tumor cell, cardiac muscle cell, macrophage, dendritic cell, neuronal cell (e.g., a glial cell or astrocyte), or pathogen-infected cell (e.g., those infected by bacteria, viruses, virusoids, parasites, or prions).

[0037] Typically, cells isolated from a specific tissue (such as epithelium, fibroblast or hematopoietic cells) are categorized as a cell-type. The cells can be obtained commercially or from a depository or obtained directly from an animal, such as by biopsy. Alternatively, the cell need not be isolated at all from the animal where, for example, it is desirable to deliver the vector to the animal in gene therapy.

[0038] The Minos transposable elements can be used to introduce a nucleic acid sequence of interest into the cells of invertebrates. For example, the Minos transposable elements can be used to introduce a DNA sequence of interest into the cells of arthropods. Arthropods include, for example, crustaceans, arachnids, myriapods and insects.

[0039] The Minos transposable elements can be used to introduce a nucleic acid sequence of interest into either germ line or somatic cells. The introduction of nucleic acid into germ line cells has the significant advantage that the nucleic acid sequence of interest will be contained in all cells of the mature progeny of the organism and transmitted to its progeny.

[0040] The Minos transposable element has been demonstrated to function in a species which is separated from the Minos source species by an evolutionary distance of 600 million years. The Minos transposable element represents the first demonstration of a mobile element which can function autonomously in the germ line of eukaryotes separated by an evolutionary distance of over 100 million years and is likely to lead to the development of a long-sought transformation system applicable across taxonomic barriers (Loukeris *et al.*, *Science* 270:2002-2005 (1995)).

[0041] However, even within the dipteran class, significant important applications for the Minos element exist. Listed below are examples of a variety of plant and animal pests, and human disease vectors which fall within the dipteran genus.

| AGRICULTURAL PESTS            | COMMON NAME         |
|-------------------------------|---------------------|
| <i>Ceratitis capitata</i>     | Medfly              |
| <i>Anastrepha</i> species     | Caribbean fruit fly |
| <i>Bactrocera oleae</i>       | Dacus               |
| <i>Bactrocera</i> species     | Oriental fruit fly  |
| ANIMAL PESTS                  | COMMON NAME         |
| <i>Cochliomya hominivorax</i> | Screw Worm Fly      |
| <i>Lucilia cuprina</i>        | Sheep blowfly       |
| <i>Simulium</i> species       | Black fly           |
| HUMAN DISEASE VECTORS         | COMMON NAME         |
| <i>Anopheles</i> species      | mosquito            |
| <i>Aedes</i> species          | mosquito            |
| <i>Musca domestica</i>        | house fly           |

[0042] Methods currently employed to control the populations of certain members of the dipteran class include the release of sterile males. An example of the utility of the germ line transformation methods of this invention includes the improvement of the existing release method. The methods of this invention can be used to improve such methods by enabling sexing schemes and for developing strains with desired characteristics (e.g., improved viability in the field).



conditional lethal genes for improved safety, and visible or molecular genetic markers for monitoring. Genetic sexing, i.e. the capability of selectively killing the females (or transforming them into males) in mass-rearing facilities, is recognized as an important need presently. Rearing and releasing only males has several advantages including lower breeding cost and the avoidance of population explosions due to inadvertent release of non-sterilized insects.

5 [0043] For example, the Mediterranean fruit fly (Medfly) *Ceratitis (C.) capitata* is a major agricultural pest for many fruit species that is geographically widespread in tropical and temperate regions. The Medfly has been introduced relatively recently into the New World, and appears to be spreading rapidly, threatening fruit producing areas in North America (Carey, J.R., *Science* 253: 1369 (1991)). Since the mid 1970's, the sterile insect technique has been used successfully for Medfly eradication and control. This method relies on the decrease in or collapse of fly populations following releases of large numbers of sterile insects over infested areas, and offers an environmentally attractive alternative to massive spraying with insecticides (Knippling, E.F., *Science* 130: 902 (1959)). The germ line transformation methods of this invention can be used to improve the sterile insect technique by, for example, enabling sexing schemes. The germ line transformation methods of this invention can also be used for developing Medfly strains with desired visible markers that can be used for monitoring effective population control.

10 [0044] The methods are also useful for insects for which it might be desirable to introduce new traits in the genetic pool, rather than controlling the population levels. For example, the presence of several sympatric sub-species of *Anopheles gambiae*, all of which transmit malaria, makes it highly unlikely that population control with biological methods such as the sterile insect technique will work. An alternative scheme might involve spreading genes for refractoriness to parasite infection into the existing populations of *Anopheles* through the use of transposable elements. Population dynamics simulations indicate that this can be effected by releasing relatively small numbers of individuals carrying an autonomously transposing element.

15 [0045] Methods for the introduction of the Minos transposon into germ line cells of diptera are analogous to those previously used in connection with other transposable elements (see, e.g., *Drosophila, A Laboratory Handbook*, Ashburner, M., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, (1989)). Briefly, the most common approach is to employ a carrier/helper transposon system. The carrier transposon is a Minos transposon which has been modified by the insertion of a DNA sequence of interest in the region of the transposon flanked by the inverted terminal repeats. Typically, sequences relating to the transposase function are deleted in order to accommodate the nucleic acid of interest. The helper transposon is a Minos transposable element which encodes an active transposase. The transposase catalyzes the transposition of the carrier transposon into the genomic DNA of the germ line of eukaryotic cells. Typically, the helper and carrier are microinjected into the posterior pole of pre-blastoderm embryos, where the precursor cells of the germ line develop.

20 [0046] An alternative to the helper/carrier system involves the purification of active transposase (for example, from an *E. coli* culture transformed with a recombinant construct encoding the Minos transposase). The purified transposase can be co-introduced into appropriately selected cells along with a carrier transposon to effect integration of the carrier into the recipient genome.

25 [0047] It has now been demonstrated that a nucleic acid sequence of interest can be introduced into a mammalian cell using the Minos transposable elements described herein. Thus, the compositions and methods of the present invention are also useful for the introduction of a nucleic acid sequence of interest into mammalian cells (e.g., mammalian somatic cell, mammalian germ line cell (sperm and egg cells)). This can be accomplished by inserting an isolated transposable element of the type described herein, modified to include the nucleic acid sequence of interest flanked by the termini of the isolated transposable element, into a nucleic acid vector, e.g., a DNA vector, such as a plasmid, virus or other suitable replicon (e.g., a viral vector), which can be present in a single copy or multiple copies. The vector can be introduced into a cell in the presence of a transposase protein or a DNA sequence encoding a transposase protein (e.g., helper plasmid) by a method appropriate to the type of cell (e.g., transformation, transfection). The transposase protein catalyzes the transposition of the modified transposable element containing the nucleic acid of interest into the genomic DNA (chromosome) of the cell. The DNA sequence encoding a transposase protein can also be inserted into a nucleic acid, virus or other suitable replicon and introduced into a cell as described herein. The modified Minos-transposable element and DNA encoding the transposase protein can be incorporated into the same or different vectors. Examples of suitable methods of transfecting or transforming cells include calcium phosphate precipitation, electroporation, microinjection, infection, lipofection and direct uptake. Such methods are described in more detail, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor University Press, New York (1989) and Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998).

30 [0048] As a particular example of the above approach to introducing the modified transposable element and/or DNA encoding a transposase protein (helper plasmid) into a mammalian cell, the modified transposable element and/or helper plasmid can be integrated into the genome of a virus that enters the cell. The virus is then introduced into the cell in the presence of a transposase protein, or a DNA sequence or virus encoding a transposase protein (helper plasmid). The modified transposable element and helper plasmid can be incorporated into the same or different viral vectors.



[0049] Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J.M., *Retroviridae: The viruses and their replication*, In *Fundamental Virology*, Third Edition, B.N. Fields, *et al.*, Eds., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus, lentiviruses and baculoviruses.

[0050] A modified transposable element containing the nucleic acid sequence of interest can also be introduced into a cell by targeting the modified transposable element to cell membrane phospholipids. For example, targeting of a modified transposable element of the type described herein can be accomplished by linking the molecule to a VSV-G protein, a viral protein with affinity for all cell membrane phospholipids. Such a construct can be produced using methods well known to those practiced in the art.

[0051] A modified transposable element, as described herein, can also be introduced into a cell in a liposome preparation or in another appropriate vehicle. The liposome preparation can be comprised of any liposomes which penetrate the cell surface and fuse with the cell membrane, resulting in delivery of the contents of the liposome into the cell. For example, liposomes such as those described in Yarosh, U.S. Patent No. 5,077,211; Redziniak *et al.*, U.S. Patent No. 4,621,023; and Redziniak *et al.*, U.S. Patent No. 4,508,703 can be used. The teachings of these patents are incorporated herein by reference.

[0052] In a particular embodiment, the Minos transposon-based method can be used to produce transgenic animals. The term "transgenic animal" is a term of art which refers to the introduction of foreign nucleic acid sequences into the germline of an animal by, for example, introduction of the additional foreign genetic material to a gamete such as the egg. As used herein, the term "foreign nucleic acid sequence" refers to genetic material obtained from a source other than the parental germplasm. As used herein, the term "foreign nucleic acid sequence" also includes genetic material obtained from the parental organism itself. Preferably, the transgenic animals are derived from mammalian embryos. The term "mammalian", as defined herein, refers to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs) and ruminants (e.g., cows, pigs, horses).

[0053] Methods for acquiring, culturing, maintaining and introducing foreign nucleic acid sequences into recipient eggs for transgenic animal production are well known in the art. See, for example, *Manipulating the Mouse Embryo: A Laboratory Manual*, Hogan *et al.*, Cold Spring Harbor Laboratory (1986). Preferably, the nucleic acid sequence of interest (e.g., foreign nucleic acid) will be delivered by the Minos-based transposon system into the embryo at a very early stage in development so that only a small frequency of the embryos are mosaic (e.g., an embryo in which integration of the foreign nucleic acid occurs after the one cell stage of development).

[0054] A transposon-based method for producing transgenic animals or for stable transfection of cells *in vitro* has very important advantages compared to the methodology presently used. For example, stable integration of nucleic acids into the germ line of several mammals is now routinely achieved by micro-injecting linear DNA molecules into the nucleus of early embryos. Some of the animals that develop from injected embryos are mosaics for integration events and in only a fraction of these the germ line is involved. Moreover, most events consist of integration of tandem repeats of the injected DNA; single-insertion events do occur at higher frequencies relative to tandem insertions if DNA is injected at lower concentrations, but at a considerable cost in time and expense because the overall transformation frequencies drop.

[0055] Using a defined transposon-transposase system can overcome some or all of these problems. First, as in *Drosophila*, it may not be necessary to have to inject the DNA into the nucleus. A mixture of transposon plus helper plasmids (or transposon plus purified transposase) that is active when introduced into the cytoplasm would enable replacement of costly and time-consuming micro-injection techniques with other methods, such as use of liposomes or viruses. Second, by controlling the relative transposon/transposase levels, the overall efficiency can be improved, with a parallel increase of the frequency of single-insertion events.

[0056] The compositions and methods of the present invention are also useful for the introduction of a nucleic acid sequence of interest into a plant cell to produce transgenic plants. As used herein, the term "transgenic plant" refers to the introduction of foreign nucleic acid sequences into the nuclear, mitochondrial or plastid genome of a plant. As used herein, the term "plant" is defined as a unicellular or multicellular organism capable of photosynthesis. This includes the

prokaryotic and eukaryotic alga (including cyanophyta and blue-green algae), eukaryotic photosynthetic protists, non-vascular and vascular multicellular photosynthetic organisms, including angiosperms (monocots and dicots), gymnosperms, spore-bearing and vegetatively-reproducing plants. Also included are unicellular and multicellular fungi.

[0057] Production of a transgenic plant can be accomplished by modifying an isolated transposable element of the type described herein to include the nucleic acid sequence of interest flanked by the termini of the isolated transposable element. The modified transposable element can be introduced into a plant cell in the presence of a transposase protein or a nucleic acid sequence or a virus encoding a transposase protein (e.g., helper plasmid) using techniques well known in the art. Exemplary techniques are discussed in detail in Gelvin *et al.*, "Plant Molecular Biology Manual", 2nd Ed., Kluwer Academic Publishers, Boston (1995), the teachings of which are incorporated herein by reference. The transposase protein catalyzes the transposition of the modified transposable element containing the nucleic acid sequence of interest into the genomic DNA of the plant.

[0058] For example, for grasses such as maize, the elements of the transposon-based method can be introduced into a cell using, for example, microprojectile bombardment (see, e.g., Sanford, J.C., *et al.*, U.S. Patent No. 5,100,792 (1992)). In this approach, the elements of the transposon-based method are coated onto small particles which are then introduced into the targeted tissue (cells) via high velocity ballistic penetration. The transformed cells are then cultivated under conditions appropriate for the regeneration of plants, resulting in production of transgenic plants. Transgenic plants carrying a nucleic acid sequence of interest are examined for the desired phenotype using a variety of methods including, but not limited to, an appropriate phenotypic marker, such as antibiotic resistance or herbicide resistance, or visual observation of the time of floral induction compared to naturally-occurring plants.

[0059] A modified transposable element, as described herein, can also be introduced into a plant cell by *Agrobacterium*-mediated transformation (see, e.g., Smith, R.H., *et al.*, U.S. Patent No. 5,164,310 (1992)) or electroporation (see, e.g., Calvin, N., U.S. Patent No. 5,098,843 (1992)), or by using laser beams (see, e.g., Kasuya, T., *et al.*, U.S. Patent No. 5,013,660 (1991)) or agents such as polyethylene glycol (see, e.g., Golds, T. *et al.*, *Biotechnology*, 11:95-97 (1993)), and the like. A modified transposable element, as described herein, can also be inserted into a nucleic acid vector (e.g. an episomal vector or a Ti plasmid vector), or virus or other suitable replicon (e.g., a viral vector), which can be present in a single copy or multiple copies. Viral vectors which can be introduced into plant cells include cauliflower mosaic virus, figwort mosaic virus, and tobacco mosaic virus.

[0060] The vector can be introduced into a plant cell in the presence of a transposase protein, a nucleic acid sequence encoding a transposase protein (e.g., helper plasmid) or a virus encoding a nucleic acid sequence encoding a transposase protein using techniques well known in the art. The method of introduction of the elements of the transposon based system into the plant cell is not critical to this invention.

[0061] The present invention also provides vectors containing an isolated Minos transposable element and nucleic acid sequence of interest. Suitable vectors for use in eukaryotic and procaryote cells are well known in the art and are, generally commercially available, or readily prepared by the skilled artisan. For example, suitable plasmids for use include pUC119 and pBlueScript KS. Additional vectors can also be found in, for example, Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998); Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed. (1989); and Gelvin *et al.*, *supra* (1995), the teachings of which are incorporated herein by reference.

[0062] The novel Minos-based stable transfection system of the present invention can be particularly useful in the delivery of one or more nucleic acid sequences of interest (e.g., genes) or products thereof to a patient. Generally, the nucleic acid sequence of interest is present or has been incorporated into the genome of the viral vector. The nucleic acid sequence or the product thereof can be a therapeutic agent. An example of a therapeutic nucleic acid sequence include RNA (e.g., ribozymes) and antisense DNA that prevents or interferes with the expression of an undesired protein in the target cell. The nucleic acid sequence of interest can also encode a heterologous therapeutic protein. A heterologous protein or nucleic acid sequence is one which does not exist in the virus as it is found in nature. Examples of therapeutic proteins include antigens or immunogens such as a polyvalent vaccine, cytokines, tumor necrosis factor, interferons, interleukins, adenosine deaminase, insulin, T-cell receptors, soluble CD4, epidermal growth factor, human growth factor, blood factors, such as Factor VIII, Factor IX, cytochrome b, glucocerebrosidase, ApoE, ApoC, ApoAI, the LDL receptor, negative selection markers or "suicide proteins", such as thymidine kinase (including the HSV, CMV, VZV TK), anti-angiogenic factors, Fc receptors, plasminogen activators, such as t-PA, u-PA and streptokinase, dopamine, MHC, tumor suppressor genes such as p53 and Rb, monoclonal antibodies or antigen binding fragments thereof, drug resistance genes, ion channels, such as a calcium channel or a potassium channel, and adrenergic receptors.

[0063] The invention can be particularly useful for vaccine delivery. In this aspect of the invention, the antigen or immunogen can be expressed heterologously (e.g., by recombinant insertion of a nucleic acid sequence which encodes the antigen) or immunogen (including antigenic or immunogenic fragments) in a viral vector. Alternatively, the antigen or immunogen can be expressed in a live attenuated, pseudotyped virus vaccine, for example. Generally, the methods can be used to generate humoral and cellular immune responses, e.g. via expression of heterologous pathogen-derived proteins or fragments thereof in specific target cells.

[0064] Generally, viral vectors which contain therapeutic nucleic acid sequences of interest are known in the art.

Examples include the vectors described in Anderson, *et al.* (U. S. Patent No. 5,399,346), Sambrook, *et al., supra*, Ausubel, *et al., supra*, and Weiss, *et al., RNA Tumor Viruses*, Cold Spring Harbor, New York (1985), the contents of which are incorporated herein by reference.

[0065] Also envisioned are the use of these viral vectors comprising a modified Minos transposable element and the transposase or nucleic acid sequence encoding the transposase protein for *in vivo* and *ex vivo* gene therapy.

[0066] Where a target cell is contacted *in vitro*, the target cell incorporating the viral vector comprising a Minos transposable element modified to include a nucleic acid of interest and the transposase or nucleic acid sequence encoding the transposase protein can be implanted into a patient for delivery of the nucleic acid of interest or product thereof. The "nucleic acid of interest" is meant to refer to a gene or RNA encoded by a gene for which the patient has an insufficiency or deficiency. The "target cell" as used herein can be migratory, such as a hematopoietic cell, or non-migratory, such as a solid tumor cell or fibroblast. Frequently, the target cell is present in a biological sample obtained from the patient (e.g., blood, bone marrow). After treatment (contact with the viral vector comprising the modified Minos transposable element and transposase protein or nucleic acid sequence encoding the transposase protein), the sample is returned or readministered to (reintroduced into) the individual according to methods known to those practiced in the art. Such a treating procedure is sometimes referred to as *ex vivo* treatment. *Ex vivo* gene therapy has been described, for example, in Kasid *et al., Proc. Natl. Acad. Sci. USA*, 87:473 (1990); Rosenberg *et al., N. Engl. J. Med.*, 323:570 (1990); Williams *et al., Nature*, 310:476 (1984); Dick *et al., Cell*, 42:71 (1985); Keller *et al., Nature*, 318:149 (1985); and Anderson, *et al.*, U. S. Patent No. 5,399,346.

[0067] The modified transposable element and helper plasmid can be incorporated into the same or separate viral vectors. Where the modified transposable element and helper plasmid are incorporated into separate viral vectors, the viral vector comprising the modified transposable element and the viral vector comprising the helper plasmid can be simultaneously or sequentially introduced into a cell. The viral vector comprising the modified Minos-transposon can be introduced into a cell prior to the viral vector comprising the helper plasmid. Alternatively, the viral vector comprising the helper plasmid can be introduced into the cell prior to the viral vector comprising the modified Minos-transposon.

[0068] The mode of administration to a patient is preferably at the location of the target cells. As such, the administration can be nasally (as in administering a vector expressing ADA) orally (as in an inhalant or spray as in administering a vector expressing the cystic fibrosis transmembrane conductance regulator (CFTR)) or by injection (as in administering a vector expressing a suicide gene to a tumor). Other modes of administration (e.g., parenteral, mucosal, systemic, implant or intraperitoneal) are generally known in the art. The agents can, preferably, be administered in a pharmaceutically acceptable carrier, such as saline, sterile water, Ringer's solution, and isotonic sodium chloride solution.

[0069] Also encompassed by the present invention is the use of the Minos transposable elements and Minos transposase to induce mutations in a cell and to identify mutations of interest in a cell. Further encompassed by the present invention is the use of the Minos transposon elements and Minos transposase to identify genes containing mutations of interest in a cell.

[0070] As used herein, the term "mutation" refers to a change or disruption in a gene which leads to a phenotype (e.g., physical, biochemical, clinical, molecular, enzymatic, immunological or pharmacological) different from that of the non-mutated cell or animal. For example, a mutation in a cell which is normally round in appearance can result in a spindle shaped cell. Similarly, a mutation in a cell which normally metabolizes a substrate can lead to an inability to metabolize the substrate. A mutation can be silent. As used herein, a silent mutation includes changes which occur in the genetic material of a cell or animal but is not distinguished from the nonmutant cell or animal on the basis of phenotype.

[0071] A gene responsible for a mutation of interest can be identified by introducing a Minos transposon, modified to include an indicator (e.g., a reporter or selectable marker gene) flanked by the termini of the isolated transposon, into a collection of cells in the presence of a transposase protein or a nucleic acid sequence encoding a transposase protein under conditions suitable for integration into the genome of a cell using techniques well known in the art. The term "indicator", as used herein, refers to a means to determine whether the transposon has integrated into the genetic material (e.g., chromosome) of a cell. For example, an indicator includes a reporter (e.g., lac Z) or selectable marker (e.g., neomycin) gene product. In a particular embodiment, the modified transposon and transposase are transfected into the collection of cells using viral vector mediated transfection schemes. Following transfection, integration can be detected. For example, in a particular embodiment, reporter gene expression can be induced under appropriate conditions and cells which have integrated into their genome the Minos transposon can be identified. Experimental conditions for the detection of reporter genes are well known in the art.

[0072] Integration of the Minos transposon can induce a mutation of interest in the genome of a cell. A cell in which the mutation of interest is present is identified by a change in phenotype and clonally propagated using standard techniques well known in the art. The phenotypic change will depend on the cell type and will be readily apparent to one of skill in the art. The gene of interest is then identified, cloned and analyzed by the presence of the Minos transposon sequence using standard molecular hybridization techniques, such as *in situ* hybridization, Southern blotting, and colony hybridization, employing the sequence (e.g., the entire sequence or a fragment thereof) of the Minos transposon element as a probe using art-recognized methods (see, e.g., Ausubel *et al., Current Protocols in Molecular Biology*,

John Wiley & Sons, New York (1998); and Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York (1989)).

[0073] A unique advantage of the transposon system described herein compared to other mutagenesis systems is the potential to be able to reverse the mutation of interest in a cell by introduction of the transposase protein or a nucleic acid sequence encoding the transposase protein. Therefore, after cloning of cells with a mutation of interest and cloning of the gene responsible for the mutation of interest, some of the clonal cells containing the mutation of interest can be subsequently used to confirm that a particular mutant phenotype is the result of integration of the modified Minos transposon. This is accomplished by the introduction into the cells of a Minos transposase protein, or a nucleic acid sequence or virus encoding a Minos transposase protein. The transposase catalyzes a site-specific excision of the transposon dictated by the inverted terminal repeats at the 5' and 3' ends of the transposon leaving behind a characteristic six base pair segment consisting of the four terminal nucleotides of either side of the transposon and the TA target site at the location of integration in the genome of the cell (Arcà, B. *et al.*, *Genetics*, 145:267-279 (1997)). The transposase excises the Minos transposon while repairing and rejoining the chromatin thereby reversing the mutation in many cases (e.g., mutant phenotype to wildtype phenotype).

[0074] The random integration of the Minos-transposon can be mutagenic in a cell *in vitro* as discussed above. As a result, the Minos-transposon and transposase can be used to induce mutations in a cell or animal. The Minos-transposon and transposase can also be used, for example, *in vivo* or *in vitro* to induce reversion of a Minos-induced mutation, as described herein. It is envisioned that the methods and compositions of the present invention can be used to induce random excision (removal) events in the genome of somatic cells during development of an animal or differentiation of a cell, thereby permitting the generation of mutations during development of an animal or differentiation of a cell. The developmental consequences of the mutations can then be evaluated. Differentiation refers to acquisition or possession of characteristics or functions differing from that of the original type. For example, a differentiated erythroblast cell is an erythrocyte.

[0075] Using the Minos-transposon and transposase of the invention, a recombination system can be employed to delete a gene segment with precision in a cell (e.g., embryonic stem cell). In a particular embodiment, an isolated Minos transposable element, modified to include a nucleic acid sequence of interest (e.g., an indicator gene) flanked by the inverted terminal repeats of the isolated transposable element is introduced into a cell. The transposon can be introduced either by the transposase-dependent methodology of the invention or by conventional transgenesis or by other means such as another transposable element. The transposon and a transposase protein, or nucleic acid modified Minos transposable element and the transposase or nucleic acid sequence encoding the transposase protein sequence or virus encoding a transposase protein are then introduced into the cell. To facilitate identification and selection of cells harboring the integrated transposon and nucleic acid sequence of interest from cells having undergone Minos transposase-mediated DNA recombination (e.g., excision), tandemly linked bacterial neomycin resistance (neo) and herpes simplex virus thymidine kinase (HSV-tk) genes are included in the modified Minos transposon vector. The neo and HSV-tk sites will serve as positive and negative selection markers, respectively. Other suitable selection markers are known in the art and can also be used. Selected cells are clonally propagated. Selection and cloning processes are techniques well known and readily available in the art.

[0076] Thus, the Minos-transposon and transposase system can be a valuable tool to mediate recombination and reverse and induce mutations in cells and transgenic animals. This method can be efficient for the introduction of deletions of defined regions and lengths in the genome of a cell.

[0077] To generate a transposon induced mutation in a gene of interest in a cell, an isolated Minos transposon modified to include an indicator is integrated into the cloned DNA sequence of the gene of interest in such a way that expression of the gene of interest is disrupted. The term "gene of interest" is used to refer to a stretch of DNA in a cell which carries the genetic information for a mRNA molecule and corresponding protein. For example, a gene of interest can be the epidermal growth factor, prolactin, P-selectin or estrogen receptor gene. "Cloned" is a term of art which refers to nucleic acid sequences manufactured by molecular biological techniques.

[0078] The introduction of the transposon into the cloned gene of interest can be achieved by conventional recombinant DNA technologies or by the transposase-induced transposition of the transposon, *in vivo* or *in vitro*, into a suitable plasmid containing the gene of interest. The plasmid is amplified and used in standard gene targeting protocols to replace the endogenous gene of interest in a cell by homologous recombination/gene conversion techniques. Endogenous means native to the cell and not derived from the cloned DNA. Homologous recombination occurs between the cloned DNA of the gene of interest and the endogenous DNA of the gene of interest thereby targeting the cloned gene of interest into the chromosome. The cells containing the targeted mutation are identified and clonally propagated using well known, routine methodologies described in detail in several art-recognized protocol texts including, for example, Ausubel *et al.*, *supra* (1998). The cells containing the targeted mutation can be evaluated experimentally. To induce reversion of the targeted mutation in a cell a transposase protein or a nucleic acid encoding the transposase protein, is introduced into a cell(s) resulting in excision of the transposon and in many instances reversion of the mutation. Mutations that can be reversed are those in which the six-base pair footprint remaining after Minos transposon excision does

not disrupt expression of the gene.

[0079] In a preferred embodiment the cells are embryonic stem cells. The embryonic stem cells are used for gene targeting and the resulting mutant cells are used to create transgenic animals and animals carrying null or "knock-out" mutations. A "knock-out" mutation refers to the disruption of a gene of interest with a complete loss of function. The

5 embryonic stem cells which contain the gene of interest integrated into their genome by the Minos-transposon system can be transmitted to the germline of an animal, such as a mouse, by injection into an early cleavage stage embryo (e.g., blastocyst) or by aggregation with two morulae to produce a chimera. "Chimera" is a term of art intended to mean an embryo containing cells or tissues with two or more genotypes. Chimeras carrying the mutated or foreign nucleic acid sequence in their germ cells are then bred to produce transgenic offspring that are entirely derived from the embryonic stem cells which carry the mutation. Genetic markers such as coat color in mice can be used to distinguish chimeras and animals derived entirely from embryonic stem cells. Experimental techniques for obtaining, propagating, cloning and injecting embryonic stem cells are well known in the art. See, for example, Evans *et al.*, *Nature*, 292:154-156 (1981); Rossant *et al.*, *Experimental Approaches to Embryonic Mammalian Development*, Cambridge University Press (1986); Sedivy *et al.*, *Gene Targeting*, W.H. Freeman and Co., New York (1992); Ausubel *et al.*, *supra* (1998).

15 [0080] The Minos-transposon approach has several advantages over the recombination techniques currently in use such as the Cre/LoxP system. For example, the introduction of nucleic acid sequences of interest is performed directly by the Minos transposon. No additional components, such as target sites, are required. In addition, using the present method, a single copy of a nucleic acid sequence of interest can be integrated and precisely excised from the genetic material of a cell in each integration step.

20 [0081] The invention also relates to the use of the Minos transposable element to identify gene enhancer elements. The term "enhancer", as used herein, refers to any cis-acting nucleic acid sequence that increases or augments the utilization of a gene promoter and can function either upstream or downstream from the promoter. An enhancer element can be close to or distant from the promoter. In this aspect of the invention, an isolated Minos transposable element is modified to include an indicator gene (e.g., nucleic acid sequence encoding a suitable reporter molecule such as  $\beta$ -galactosidase or a selectable marker (e.g., neomycin resistance) flanked by the inverted repeats of the isolated transposable element, which is optionally linked to minimal promoter (e.g., a TATA box sequence). As used herein, the term "minimal promoter" includes nucleotide sequences upstream from the Minos transposon that can weakly initiate transcription.

[0082] For enhancer detection methods, the nucleic acid sequence comprising a minimal promoter and Minos transposable element, modified to include an indicator gene (e.g., a reporter gene such as lacZ) or selectable marker such as neomycin gene), is incorporated into a suitable vector, as described herein, and introduced into a population (or sample) of cells under conditions appropriate for integration into the genome of a cell in the presence of a transposase protein or a nucleic acid sequence or virus encoding a transposase protein. Integration into the genome of a cell at or near an enhancer site can be detected by the indicator. For example, selection of cells or detection of the reporter gene product. It is expected that varying ranges of signal, in the case of a reporter gene, and selection, in the case of a selectable marker, can occur depending upon the strength of the enhancer. Once an enhancer region has been identified by, for example, expression of a reporter gene, the enhancer site can be located within the genome by standard hybridization protocols (e.g., *in situ* hybridization and Southern blotting with Minos transposon specific probes) and the resulting sites readily cloned and analyzed. Experimental conditions for the detection of reporter and selectable marker genes as well as hybridization techniques and genomic sequencing are well known in the art.

40 [0083] The methods and compositions of the present invention can also be used to detect and trap an exon of a gene in a cell. The term "exon", as used herein, is any segment or region of a gene which is represented in the mature mRNA transcription product. Most eukaryotic genes and some prokaryotic genes include additional nucleic sequences referred to as introns that are within the coding region of a gene but do not appear in the mature mRNA. Introns are dispersed among the exons in the genetic material of cells. To identify an exon of interest in a gene, an isolated Minos transposable element is modified to include an indicator gene (e.g., reporter or selectable marker gene) lacking a translation initiation codon but linked to a splice acceptor sequence and flanked by the inverted terminal repeats of the isolated transposable element. The modified transposable element is incorporated into an appropriate vector and introduced into a population of cells in the presence of a transposase protein or a nucleic acid sequence encoding a transposase protein. In a particular embodiment, the modified transposable element and/or the transposase is incorporated into a viral vector, which is introduced into a population of cells. Random integration of the transposon into an intron of a gene in the correct orientation can result in transcription of hybrid mRNA encoding, for example, an indicator gene, such as a reporter or marker gene. mRNA transcribed from a gene disrupted by integration of the modified transposon in an intron results in a change in mRNA splicing patterns compared to the gene lacking the integrated transposon in such a way that a hybrid mRNA is produced carrying, for example, the reporter or marker gene as an exon. This change in splicing pattern signifies the presence of an exon. Genes targeted in this way can be isolated by virtue of their being linked to the Minos transposon. Methods for transfection, reporter gene expression, selection conditions, mRNA isolation, reverse transcription protocols, nucleic acid sequencing and hybridization techniques are all well known art-

recognized technologies. Exemplary discussions and detailed protocols can be found in Ausubel *et al.*, *supra* and Sambrook *et al.*, *supra*.

[0084] The gene- and enhancer-trapping strategies described above can provide for a novel and relatively simple method of identifying developmentally regulated genes. For example, reporter genes lacking promoters can be randomly integrated into the genome of a cell by using the Minos-based transposon system described herein. For example, a modified transposon element containing a "promoter-less" reporter gene can be introduced into mouse embryonic stem cells, which are then introduced into embryos. Screening for expression of the reporter gene permits the identification of endogenous genes which become transcriptionally active in the developing embryo or in the embryonic stem cells *in vitro*. The molecular tag provided by the Minos transposon enables developmentally expressed and regulated genes to be readily identified, cloned and analyzed.

#### METHODS FOR ISOLATING ADDITIONAL Tc-1 FAMILY MEMBERS

[0085] DNA sequence analysis of the members of the Minos family disclosed herein, and comparison of this sequence information to the sequences of Tc-1 family members from evolutionarily distant organisms (e.g., nematode), reveal short stretches of conserved amino acid sequence within the transposase coding region. This high degree of conservation suggests a method for isolating Tc-1 family members from diverse eukaryotic species.

[0086] This method involves the amplification of DNA by polymerase chain reaction from a eukaryote of interest using primers which are complementary to a sequence of at least about 12 consecutive nucleotides which encode amino acids which are highly conserved in aligned sequences of nematode Tc-1 family members and dipteran Minos family members. Such amino acid sequences include, for example, MVWGC (SEQ ID NO:10), WPSQSPDL (SEQ ID NO:11) and WPSNSPDL (SEQ ID NO:12).

[0087] The present invention will now be illustrated by the following examples, which are not intended to be limiting in any way.

#### EXAMPLES

##### EXAMPLE 1

#### MATERIALS AND METHODS

##### [0088]

##### 1. FLY STRAINS

Standard procedures were used for culturing of *Drosophila hydei*. All strains used in this study have been used previously for rDNA work and are named for the X and Y chromosomes. Strain  $bb^1$  ( $bb^1/bb^1 \times bb^1/Y$ ) carries a bobbed X chromosome; strain  $X^7$  ( $X^7/X^7 \times X^7/Y$ ) is a subline of the Dusseldorf wild-type strain; strain  $X^A X^Y$  ( $X^A X^Y \times X^Y$ ) females carry a compound X chromosome which has no rDNA. Strain  $wm1/Y$  ( $wm1/Y \times X-3/Y$ ) females have a compound X chromosome ( $wm1$ ); males carry a X-autosome 3 translocation which has no rDNA.

##### 2. DNA MANIPULATIONS AND SEQUENCING

All basic procedures were carried out essentially as described (Maniatis *et al.*, 1982). DNA from adult females of strain  $bb^1$  was partially digested with EcoRI and cloned into phage vector  $\lambda$ gt7. To recover new Minos elements, the library was screened by hybridization with a 1.7 kb HhaI fragment which contains most of the Minos-1 sequence. For sequencing, the appropriate restriction fragments from positive clones were subcloned into plasmid vectors pUC8 and pUC9 and nested deletions were generated by digestion with exonuclease Bal31 followed by subcloning. Sequencing was performed by conventional methods. Both strands were sequenced, with a minimum of two independent sequences for each base pair.

##### 3. SEQUENCE ANALYSIS

Database searches and sequence analysis and manipulations were performed using programs FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448 (1988)), BLAST (Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990)) and the computer package GCG (Devereux *et al.*, *Nuc. Acids Res.* 12:387-395 (1984)). The program CLUSTAL (Higgins and Sharp, 1988) was used for protein sequence alignments.







## 3. COMPARISON OF THE PROTEINS ENCODED BY Tc1 AND MINOS

[0094] The deduced 201 amino acid sequence of the ORF2 in Minos-2 and Minos-3 shows significant sequence similarity with the 201 carboxy terminal residues of TcA, the putative transposase of Tc1; alignment of the sequences gives 63 identities (31%) and 91 conservative substitutions (45%) with only two single-residue insertion-deletions. The two sequences, however, differ in size; TcA has 72 additional amino acids at the amino end. The 50 amino-terminal residues of TcA show weak but significant sequence similarity with the carboxy terminus of Minos ORF2; introduction of a 60-bp deletion in the Minos DNA sequence creates a long open reading frame which contains most of ORF1 (codons 1 to 138) and the entire ORF2 extended by 22 codons upstream of the ATG. Interestingly, this 60-bp sequence, from base 752 to base 811 of the Minos sequence, exhibits features of an intron. More specifically, the 5' and 3' ends conform to the consensus splice donor and acceptor sites and a version of the internal splice signal consensus is found 30 nucleotides upstream from the 3' end.

## 4. DIVERGENCE OF THE TcA-RELATED SEQUENCES

[0095] Although Minos inhabits a *Drosophila* species, it is not more related to the other Tc1-like elements from *Drosophila* species, HB1 and Uhu. These elements, or at least the members which have been sequenced, do not contain open reading frames comparable in length to that of Tc1. However, if small numbers of deletions and insertions are introduced in their DNA sequences, open reading frames can be generated which show significantly similarity with the TcA sequence. Most of these insertion-deletion changes involve one nucleotide, presumably representing mutations which have accumulated in these inactive elements. Table 1 shows a similarity matrix between the three *Drosophila* and the two nematode elements, in the regions corresponding to the hypothetical Minos exon 2. In Table 1, percent identities are shown above the diagonal; identical/total positions are shown below the diagonal. Minos shows approximately the same degree of similarity (between 28 and 36 percent identity) with all the other elements; HB1 and Uhu show comparable similarities. In a multiple sequence alignment of the same regions, 21 of the resulting 225 positions (9%) are invariant and 49 positions (22%) are occupied by related amino acids. It should also be noted that the similarity between HB1 and Uhu with Tc1 and Minos extends another 18 codons upstream from the position corresponding to the first codon of the hypothetical exon 2 of Minos. No other significant similarities can be detected between Tc1, Uhu, HB1 and Minos in the sequences between the terminal repeats.

TABLE 1

|       | Tc1     | TCb1   | Minos  | Uhu    | HB1 |
|-------|---------|--------|--------|--------|-----|
| Tc1   |         | 71     | 31     | 44     | 33  |
| TCb1  | 160/223 |        | 34     | 41     | 35  |
| Minos | 70/221  | 75/222 |        | 36     | 28  |
| Uhu   | 96/217  | 89/217 | 78/218 |        | 31  |
| HB1   | 73/223  | 79/223 | 62/222 | 68/219 |     |

## 5. THE ORF1 SEQUENCE IS RELATED TO THE PAIRED BOX SEQUENCE

[0096] Searches of the nucleic acid and protein sequence data libraries with the ORF1 sequence using the FASTA and WORDSEARCH algorithms gave no significant matches. However, the Basic Local Alignment Search Tool program revealed a similarity with the paired box sequence, a peptide sequence found in the *Drosophila* paired gene product, and conserved in other *Drosophila* and mammalian genes. This similarity extends approximately between residues 1 to 96 of the Minos sequence, and residues 35 to 131 of the *Drosophila* paired protein. Alignment of the Minos sequence with the *Drosophila* and human paired box sequences for maximum similarity shows 16 invariant positions in this region (17%) and 49 positions occupied by related amino acids (51%). The corresponding values for the human and *Drosophila* paired sequences are 72% identities and 23% conserved positions.

[0097] Although the Minos-paired similarity is weak compared to that between the *Drosophila* and human paired sequences, it is statistically significant. The similarity scores between the Minos sequence (amino acids 1 to 118 of ORF1) to the corresponding human paired sequence (amino acids 17 to 135 of the published sequence) is approximately 10 standard deviations higher than the average of the scores obtained from 50 comparisons made between the Minos sequence and 50 randomly shuffled human paired sequences.

6. TRANSPOSITION IN *D. melanogaster*

[0098] A *D. melanogaster* "helper" strain which can overproduce the Minos transposase upon exposure to heat shock was constructed. The strain was constructed by introducing a modified Minos element into the germ line by conventional P element transformation (see, e.g., *Drosophila*, "A Laboratory Handbook", Ashburner, M., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, (1989)). To place the Minos transposase under heat shock control, the left-hand terminal repeat of Minos-2 was replaced by the *D. melanogaster* hsp 70 promoter. This modified element was inserted into the P element transformation vector pDM30, which contains a wild-type copy of the *Drosophila* rosy (ry) gene as a dominant visible marker. The plasmid (pPhsM2) was injected into pre-blastoderm embryos of a ry strain, injected GO adults were mated to ry flies and ry<sup>+</sup> G1 progeny were bred further. Three independent transformants were recovered, two on the third chromosome (named M46 and M67) and one on the X (M84). Southern blots using ry and Minos probes indicated that each of the three transformants contains a single insertion of the complete sequence between the P element ends. Northern blots of total RNA from adult transformed flies subjected to a heat shock showed abundant transcripts hybridizing to Minos probes. No Minos-related transcripts have been detected by the same probes in RNA from non-heat shocked flies. The structure of the RNA transcripts was investigated in another series of experiments discussed below.

[0099] Breeding of these transformants showed that they are all homozygous lethal. This observation was unexpected; the recovery of recessive lethal mutations due to insertional inactivation of essential genes is a rather uncommon event in P transformation experiments. Moreover, the insertion into the X clearly has not caused a "knock-out" mutation since hemizygous males are viable and fertile; only homozygous females are inviable. This behavior suggested that the lethality may be dosage- or pairing-dependent; the latter being more likely because double heterozygotes of the two insertions in the 3rd chromosome are viable. The observed lethality is a useful feature which enables one to follow the segregation of the "helper" chromosomes by keeping them over genetically marked balancers.

[0100] Strong evidence for Minos transposition in the germ line was obtained by first introducing the M67 chromosome into a white background (y,w; TM3/M67). Pre-blastoderm embryos were injected with a plasmid (pM2w) containing a complete Minos-2 element with a wild-type copy of the white (w) gene inserted into its unique EcoRI restriction site within ORF2. The inserted w sequences provide a dominant selectable marker; in addition they interrupt ORF2, making the production of active transposase from this construct highly improbable. Three separate experiments were conducted: In experiment A injected embryos and the developing larvae and adults were kept at 18 degrees C, in experiment B they were kept at 25 degrees C throughout development, and in experiment C the embryos were subjected to a 1-hour 37°C heat shock three hours after injection. All emerging GO flies (63, 38 and 61, from experiments A, B and C, respectively) were mated to y,w; TM3/Dgl3 flies and the progeny were scored for the appearance of the w<sup>+</sup> phenotype. To date, at least four independent germ line transformation events have been detected in experiments A and B. Two of these events come from a single GO male from experiment A and at least two have been recovered from two different GO flies from experiment B. The results are shown in Table 2 below:

TABLE 2

| Experiment | GO  | #G1 Scored | w <sup>+</sup> G1 | Insertion Chromosome |
|------------|-----|------------|-------------------|----------------------|
| A          | A10 | 286        | A10.1             | X                    |
|            |     |            | A10.2             | 3                    |
|            |     |            | A10.3             | 3                    |
|            |     |            | A10.4             | -                    |
|            |     |            | A10.5             | -                    |
|            |     |            | A10.6             | -                    |
| B          | B13 | 75         | B13.1-3           | -                    |
| C          | B33 | 116        | B33.1-18          | -                    |

[0101] Evidence that the Minos-w<sup>+</sup> transposon can be mobilized in the soma of flies which produce the transposase has been obtained. Larvae of the constitution y,w; TM3/[M2w]M67 (progeny of the A10.2 fly), which contain both transposon and helper sequences, were subjected to heat shock and adult flies were examined for the appearance of eye color mosaicism. More than 50% of the flies showed mosaicism of different degrees. Patches of ommatidia with either reduced or increased pigmentation were observed which is consistent with the expected result of a somatic deletion or

transposition event. No mosaicism has been detected in flies not subjected to a heat shock at the larval stage. The somatic instability results clearly indicate that the  $w^+$  insertions are minos-mediated.

## 7. ANALYSIS OF MINOS mRNA TRANSCRIPTS

[0102] Total RNA was isolated from the M67 strain, the construction of which is described above. The structure of mRNA transcripts was investigated by the polymerase chain reaction (PCR) method of DNA amplification. A particularly important aspect of this investigation was to determine the status of the 60 base pair putative intron region (discussed above) in the mRNA transcripts. As was mentioned previously, this sequence is characterized by 5' and 3' ends which conform to the consensus splice donor and acceptor sites, and has a version of the internal splice signal consensus sequence 30 nucleotides upstream from the 3' end.

[0103] To determine the status of this putative intron, PCR priming sites were selected from exon sequences (ORF1 and ORF2) flanking the putative intron. The PCR product synthesized in this reaction was cloned and sequenced by conventional methods. The sequencing experiments revealed unambiguously that the 60 base pair intron sequence was, in fact, absent in the amplified DNA.

[0104] The removal of the 60-bp sequence in the correctly spliced primary transcript initiating upstream from ORF1, results in the generation of a 1023-bp open reading frame which encodes a peptide of 341 amino acids. An alignment of the 273 carboxy-terminal amino acids of this peptide with the sequences of TcA and the 273-residue hypothetical peptide of Tcb1 was generated by the multiple alignment program CLUSTAL, which introduces gaps in the sequences to achieve maximum sequence similarity. The three sequences were aligned without the need of any insertions-deletions (with the exception of the two one-residue gaps required for optimal alignment in the ORF2 region) and show an overall 28% identity, i.e. 76 of the 273 positions are invariant. In the region upstream from the first methionine of ORF2, twelve out of seventy two positions (16%) are invariant; 29 positions (40%) are occupied by structurally related amino acid residues. Although this degree of similarity is lower than that in the ORF2 region, it is statistically significant.

[0105] The sequence similarity between TcA and the carboxy end of the Minos hypothetical protein is also reflected in their secondary structures. Comparisons of  $\alpha$ -helix and  $\beta$ -sheet predictions and hydrophobicity profiles between the Tc1 and Minos sequence show similarities in several regions. Another feature of the sequences is their high content, approximately 20%, in basic amino acids. TcA has 29 arginines, 16 lysines and 11 histidines, and the TcA-related Minos sequence has 20 arginines, 32 lysines and 4 histidines. These are more abundant at the amino-terminal half of both sequences, although the position of most is not strictly conserved. The proteins are fairly basic, with computed isoelectric points of 11.27 for TcA and 10.73 for the related Minos peptide. The computed pI of the complete hypothetical 361 amino acid Minos protein is 10.97.

## 8. GENE TRANSFER INTO *C. capitata* USING MINOS TRANSPOSABLE ELEMENTS

[0106] Single copies of exogenous DNA can be introduced into the genome of *C. capitata* by using a germ line transformation system which utilizes the transposable element *Minos* to mediate precise integration of DNA at acceptable frequencies.

[0107] To provide an effective dominant selectable marker for detection of transformants, an approximately 3.7 kb *NotI* fragment containing the wild-type *white* eDNA of *C. capitata*, flanked by the *D. melanogaster* hsp 70 promoter and terminator sequences, was inserted into the *NotI* site of the Minos vector pMiNot which was constructed by replacing a 644 bp *MscI* fragment of the Minos transposase gene (nucleotides 618 to 1264 of Figure 2A-2C) with a *NotI* linker. This modified element (shown in Figure 3A) was inserted into the *E. coli* vector pTZ18R (Pharmacia), creating a plasmid (pMihsCcw) having a wild-type copy of the *C. capitata* *white* (*w*) gene as a dominant visible marker.

[0108] To place the Minos transposase under heat shock control, the left-hand terminal repeat of Minos-2 was replaced by a 456 bp fragment containing the *D. melanogaster* hsp 70 promoter. This modified element (shown in Figure 3B) was inserted into the *E. coli* vector pTZ18R (Pharmacia), creating the transposase-producing plasmid pHSS6hsMi.

[0109] The plasmids pMihsCcw and pHSS6hsMi were introduced into pre-blastoderm Medfly *w/w* embryos by a microinjection procedure similar to that used for *Drosophila*. For egg collecting, flies were mass-reared in population cages at 24°C. Eggs were collected at 24°C for 60 minutes, and then were dechorionated, desiccated and microinjected at 18°C with a mixture of 100 mg/ml helper and 400 mg/ml transposon plasmid DNA as described for *Drosophila* embryos (Rubin, G.M. and Spradling, A.C., *Science* 218: 348 (1982)). Modifications of the procedure were not necessary, because the eggs of the two species are similar in morphology and in resistance to desiccation.

[0110] A total of 3,998 embryos were injected. After injection, they were left to hatch under halocarbon oil, and first instar larvae were transferred to Petri dishes containing standard larval food (Mintzas, A.C. *et al.*, *Dev. Biol.* 95: 492 (1983)). The 390 adults (G0 generation) resulting from injected embryos were collected within 12 hours after eclosion and back-crossed to *w* flies in small groups consisting of either 5 G0 males and 10 virgin *w* females, or 10 G0 females

and 5 *w* males. Fifty-nine such G0 groups were reared in small plastic cages and the G1 progeny were collected and handled separately for each group. To induce expression of the *w* mini-gene from the *Hsp70* promoter, G1 pupae were exposed daily to a 39°C heat shock for one hour. The 62,510 G1 flies that were produced were screened for the presence of non-white eye phenotypes. As shown in Figure 4, a total of 72 flies with colored eyes were recovered from four different cages.

[0111] The *w* mini-gene gives partial reversion of the phenotype. Eye color varies in strength among different transformants. The phenotype is dosage-dependent with homozygotes having stronger colors than heterozygotes. These characteristics of *w* markers are useful in sorting multiple insertions and in distinguishing homozygous from heterozygous transformants. The characteristics are due to low levels of expression combined with chromosomal position effects and have been observed previously in *Drosophila*.

[0112] To establish transformed lines, individual G1's were initially back-crossed to *w* flies. Single pairs of transformed G2 progeny were then mated, and their homozygous G3 progeny, recognized by their stronger *w*<sup>+</sup> phenotypes, were used to construct homozygous lines. Table 3 shows the results from the G1 back-crosses. In these crosses, the non-white eye (*w*<sup>+</sup>) phenotype was inherited as a single, dominant trait.

[0113] To determine the effect of temperature on the expression of the *w* mini-gene, a number of G2 pupae were not subjected to the heat shock treatment. When compared to the heat-shocked cohort, G2 flies which had not been heat shocked as pupae showed either paler eye color or no eye color at all; the only exception was lines 3.1 and 3.3, which exhibited an invariant strong yellow eye phenotype. The heat shock dependence clearly showed that the flies (perhaps with the exception of 3.1 and 3.3) were true transformants, rather than revertants of the *w* mutation. In cages 3 and 25, differences in the eye color phenotypes of individual G1's from the same cage were detected and bred true, suggesting that independent transformation events had occurred in the same cage.

TABLE 3

| G1   | Eye color of heterozygotes | With heat shock |            | Without heat shock |            | Eye color of homozygotes |
|------|----------------------------|-----------------|------------|--------------------|------------|--------------------------|
|      |                            | non-white eyes  | white eyes | non-white eyes     | white eyes |                          |
| 1.1  | pale yellow                | 46              | 53         | 0                  | 59         | apricot                  |
| 1.8  | pale yellow                | 220             | 274        | 0                  | 77         | apricot                  |
| 1.12 | pale yellow                | 94              | 69         | 0                  | 8          | apricot                  |
| 3.1  | yellow                     | 267             | 237        | 110                | 97         | yellow                   |
| 3.3  | yellow                     | 225             | 214        | 53                 | 49         | yellow                   |
| 3.2  | pale yellow                | 132             | 118        | 0                  | 76         | apricot                  |
| 3.6  | pale yellow                | 70              | 81         | 0                  | 81         | apricot                  |
| 25.7 | pale apricot               | 119             | 156        | 116*               | 91         | apricot                  |
| 25.8 | pink                       | 24              | 18         | 0                  | 27         | peach                    |
| 25.9 | pink                       | 30              | 34         | 0                  | 9          | peach                    |
| 33.2 | pale orange                | 42              | 50         | ND                 | ND         | orange                   |
| 33.3 | pale orange                | 29              | 31         | ND                 | ND         | orange                   |
| 33.4 | pale orange                | 16              | 15         | ND                 | ND         | orange                   |

\* Eye color much weaker than with heat shock.

[0114] To determine the nature of the integration events, DNA from transformants was analyzed by Southern blot hybridizations using several restriction enzymes and two probes (see Figure 3A), one (M) containing the *Minos* sequences at the ends of the transposon (which are not present in non-transformed *Medfly*), and another (W) containing an internal fragment of the *w* cDNA sequences (which is present in the endogenous *w* gene).

[0115] Adult genomic DNA (approximately 10 µg per lane) was digested with a restriction endonuclease, subjected to agarose gel electrophoresis, blotted onto nitrocellulose membrane filters and hybridized with <sup>32</sup>P-labeled probes. Membranes were pre-hybridized for 6 hours at 65°C in 7% SDS, 0.5 M phosphate buffer pH 7.4, 1 mM EDTA. Hybridization was for 12-14 hours at 65°C in 7% SDS, 0.5 M phosphate buffer pH 7.4, 1 mM EDTA. Excess probe was removed.

by two 10-minute washes with 5% SDS, 40 mM phosphate buffer pH 7.4, 1 mM EDTA at 65°C followed by a 20-minute wash at room temperature with the same buffer pre-warmed at 65°C.

[0116] DNA from lines 3.1, 3.2, 3.3 and 3.6 was cut with *SalI* and hybridized with a 1 kb *HhaI* fragment containing *Minos* sequences present in pMiNot (M probe of Figure 3A).

[0117] DNA from the recipient *w* strain and from lines 3.1, 3.2, 3.3 and 3.6 was cut with *HincII*, and probed with a *SalI/XhoI* fragment containing 1.5 kb of Medfly *w* cDNA sequences (W probe of Figure 3A) and with the M probe. Between the two hybridizations the filter was dehybridized by washing with boiling 0.5% SDS solution for 2 minutes.

[0118] In *Drosophila*, insertions of elements like *Minos* can occur at many different chromosomal sites, and are characterized by precise integration extending through the terminal inverted repeats of the element without transposition of any flanking plasmid DNA. The results of M-hybridized *SalI* digests document that the events in the Medfly are of the same nature. The transposon has inserted variable host DNA sites, and no significant (> 0.2 kb) flanking plasmid DNA to the right of the transposon can be present, because this would have been signaled by the presence of a 2.9 kb band. The results also confirm that two independent events have occurred in cage 3, one represented by lines 3.1 and 3.3 and the other by lines 3.2 and 3.6 (cf. Table 3). These conclusions were also confirmed with *HincII* digests. Similarly, blots of *HincII* digests hybridized with the W probe showed the two endogenous *w* gene bands, plus a third novel band that is characteristic of the insertion event (3.1/3.3 or 3.2/3.6). The shortest band is longer than the 1.9 kb band that would have been expected if the *HincII* site, 0.2 kb to the right of the *Minos* end (see Figure 3A) had been present. The same *HincII* blot hybridized with the M probe showed that the shortest band is longer than the 1.1 kb band that would have been expected if plasmid sequences to the left of the transposon were present. These results were confirmed with W-hybridized *SalI* digests.

[0119] To assess the integrity of the internal part of the transposon, restriction analysis using *EcoRI* was performed in three lines derived from cage 25. DNA from strains 25.7, 25.8 and 25.9 was cut with *EcoRI* and hybridized with the W and M probe sequentially. In addition to the transformants showing non-white eye phenotypes white-eyed siblings (25.9-w, 25.8-w, 25.7-w) were included in this analysis. The results of the hybridization with the W probe indicate that the entire 3.7 kb fragment containing the *Hsp70/w* marker fusion is present in the *w*<sup>+</sup> transformants. Hybridization of the same filter with the M probe, which detects "chimeric" end fragments, showed that lines 25.8 and 25.9 contain the same, single insertion of the transposon. The pattern in 25.7 is consistent with the presence of two insertions, neither identical to the 25.8/25.9 event. One of these insertions, defined by the ~3 kb and ~5.5 kb bands, is also present in the white-eyed siblings of the 25.7 flies. This, presumably, represents a "silent" insertion that does not express the phenotype either due to an undetected lesion in the transposon, or because the transposon has integrated into a silent (perhaps heterochromatic) genomic region.

[0120] Restriction analysis of the transformants revealed that, as predicted by the phenotypes (Table 3), two independent transformants were represented among the G1 progeny of cage 3, two in cage 25, and one in cage 33 (Data for transformants from cage 33 are not shown. The restriction patterns of three G1's from cage 1 were identical to these of the 3.2/3.6 event. Evidently, a G0 male present in cage 3 had mated with a G0 female of cage 1, before the G0 flies were sorted into cages.) Only one of these 5 transformants (25.7) had a second (phenotypically silent) event in the same germ line. The different transformants from the same cages are derived either from single or multiple G0 parents. The overall frequency of phenotypically detectable transformation events (5/390 G0 adults) is sufficient for producing several transformants from a single experiment since thousands of embryos can be injected and hundreds of G0 adults can be obtained within a week using a relatively simple experimental setup.

[0121] To confirm the presence of a single *Minos* insertion in transformant 3.1, third instar larva salivary gland polytene chromosomes were prepared and *in situ* hybridization were performed essentially as described previously (Zacharopoulou, A., et al., *Chromosoma* 101: 448 (1992)). The 3.7 kb *NotI* fragment containing the *Hsp70/w* minigene fusion was used as probe. Hybridization to polytene chromosomes of salivary glands from transformed third instar larvae confirmed the presence of single *Minos* insertions, allowing their cytological localization.

## EXAMPLE 2

### MATERIALS AND METHODS

#### 1. TRANSFECTION OF MAMMALIAN CELLS

[0122] Human HeLa cells and green monkey COS1 cells were cultured at 37°C in an atmosphere containing 4% CO<sub>2</sub> in DMEM supplemented with 10% fetal calf serum (FCS) and 50 µg/ml gentamycin. HeLa cells were seeded onto 60 mm dishes (300,000 cells per dish) and COS1 cells were seeded onto 6-well plates (200,000 cells per well) one day prior to transfection.

## 2. HELA CELL TRANSFECTIONS

[0123] HeLa cells were transfected with Qiagen (Qiagen) and Elutip (Schleicher and Schuell)-purified supercoiled plasmid DNA in 2.5 ml DMEM supplemented with 2% FCS and 50 µg/ml gentamycin and 0.5 ml of a calcium/HBS precipitant, according to the calcium chloride procedure described by Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York (1989)).

[0124] HeLa cells were transfected with either 8 µg of transposon plasmid pMiLRneo (Figure 6) alone; a mixture of 8 µg of the transposon plasmid pMiLRneo (Figure 6) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5); or a mixture of 8 µg of the "wings clipped" plasmid pMiLneo (Figure 7) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5). The "wings clipped" plasmid includes a modified Minos transposon in which one of the inverted repeats has been excised.

[0125] The pMiLneo transposon plasmid and the "wings clipped" plasmid include a selectable neomycin (neo) resistance gene, which is under the control of the SV40 early promoter (e.g., operably linked). The neo gene encodes a prokaryotic aminoglycoside phosphotransferase that detoxifies the antibiotic G418 which blocks protein synthesis in eukaryotic and prokaryotic cells, thereby allowing for selection and growth of colonies containing inserts (transfected cells).

[0126] After 16 hours of incubation with DNA, the cells were washed twice with serum-free DMEM and re-fed with 4 ml of serum containing (10% FCS) DMEM. Two days post-transfection, the cells were trypsinized and seeded onto 150 mm (Experiment #1, Table 4) or 90 mm (Experiments #2 and #3, Table 4) dishes with DMEM-10% FCS containing 600 µg/ml G418 (Gibco-BRL). After 15 days of selection, cell clones were either isolated and expanded into individual cultures, or fixed in a solution containing 10% (v/v) formaldehyde in PBS for 15 minutes. Fixed cells were stained with 2% (w/v) methylene blue in PBS and colonies counted.

## 3. COS CELL TRANSFECTIONS

[0127] COS1 cells were prepared for transfection. Transfection selection was performed as described for the HeLa cells, except that COS cells were transfected with a mixture of 3 µg supercoiled pEF1/ILMi helper plasmid DNA (Figure 5) and 3 µg supercoiled pQB125 (Quantum) plasmid DNA. Colonies were fixed in 10% formaldehyde in PBS. Expression and cellular localization of the plasmid DNA encoding the transposase was determined by indirect immunocytochemical techniques using a polyclonal antisera for Minos transposase and a rhodamine-conjugated goat anti-rabbit antibody.

## RESULTS

### 1. TRANSPOSASE-INDUCED STABLE TRANSFECTION OF HeLa CELLS WITH A MINOS TRANSPOSON.

[0128] As shown in Table 4, HeLa cells transfected with transposon plasmid pMiLRneo in the presence of the helper plasmid pEF1/ILMi, which encodes a transposase, resulted in a 19-fold (Experiment #1), a 18-fold (Experiment #2) and a 14.5-fold (Experiment #3) increase in the rate of recovery of stable transfectants, compared to transfection with the transposon plasmid pMiLRneo alone.

[0129] The transfection depends upon the presence of two functional Minos inverted repeats in the transposon plasmid, since transfection in the presence of the "wings clipped" transposon and the helper plasmid results in numbers of colonies roughly equivalent to the number of background colonies produced by transfection with transposon plasmid alone.

[0130] Moreover, the percentage of HeLa cells transfected by the Minos-based system was surprisingly high (e.g., 2.5% in Experiment #1) compared to previously described methods used to transfect mammalian cells. Existing transfection methods generally result in very low percentages of stably transfected cells. In the present experiments, between  $10^{-4}$  and  $10^{-3}$  stably transfected cells were obtained by using the calcium co-precipitation method as described in Ausubel *et al.*, *supra*. (see Chapters 9.1.11 and 9.5.1 (1998)). For example, in Experiment #1, the stable transfection efficiency was 25- to 250-fold higher than that obtained by conventional methods. Thus, the present invention is a new and improved method for transfecting cells including mammalian cells.

TABLE 4

| EXPERIMENT | Transposon |       | Transposon+Helper |      | "wings clipped" + Helper |       |
|------------|------------|-------|-------------------|------|--------------------------|-------|
|            | A          | B     | A                 | B    | A                        | B     |
| #1         | 800        | 0.13  | ~15,000           | 2.5  | -                        | -     |
| #2         | 250        | 0.041 | 4,500             | 0.75 | -                        | -     |
| #3         | 200        | 0.033 | 2,900             | 0.48 | 300                      | 0.020 |

A = Number of Transfected Colonies

B = Percent of Cells Transfected

[0131] These data show that co-transfection of a human cell line with a plasmid carrying a Minos transposon and the Minos transposase gene results in integration of a nucleic acid sequence.

[0132] These data show that both transposase and the presence of two Minos ends are necessary for integration into the genome of cells (e.g., mammalian cells). Therefore, the data show that the integration effect of the Minos transposase is a result of its specific enzymatic function.

[0133] For example, in insect cells, transposases of Type II mobile elements like the Minos transposase, function by binding at or near the inverted repeats of the transposon and catalyzing the precise excision of the entire transposon (i.e. the DNA flanked by and including the inverted repeats) from its position and precise re-insertion into DNA. Like other known elements belonging to the same family of transposons with Minos, insertion of the Minos transposon into DNA is not entirely random. The element inserts at a TA dinucleotide via a mechanism that causes duplication of the target TA. In this way, transposase-mediated integrations of Minos can be characterized by the presence of intact inverted repeats flanked by TA dinucleotides. Consequently, the molecular basis of the Minos transposon insertions in the stably transfected HeLa cells can be determined by Southern blot analysis of the DNA from G418 resistant colonies, and can be confirmed by cloning and sequencing of individual insertions from these sublines.

## 2. EXPRESSION AND NUCLEAR LOCALIZATION OF MINOS TRANSPOSASE IN TRANSIENTLY TRANSFECTED COSI CELLS

[0134] Minos transposase was localized in the nuclei of the cells, documenting expression of the Minos transposase and transport into the nuclei. Nuclear localization of Minos transposase is consistent with the function of Minos as a transposase and the presence of several nuclear localization signals consisting of stretches of amino acid residues with basic side chains in its primary amino acid sequence.

## 3. DETERMINATION OF INTEGRATION EFFICIENCY

[0135] To determine the efficiency of integration of the Minos transposon into chromosomes after transfection, HeLa cells were co-transfected with 1 µg of the GFP-expressing plasmid pIRES/GFP (Clontech) and either (a) a mixture of 8 µg of the transposon plasmid pMiLRneo (Figure 6) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5); (b) a mixture of 8 µg of the transposon plasmid pMiLRneo (Figure 6) and 2 µg of the plasmid pEF1; (c) a mixture of 8 µg of pMiLRneo (lin.) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5); (d) a mixture of 8 µg of pMiLRneo (lin.) and 2 µg of the plasmid pEF1; (e) a mixture of 8 µg of pMiLRneo (dig.) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5); (f) a mixture of 8 µg of pMiLRneo (dig.) and 2 µg of the plasmid pEF1; or (g) a mixture of 8 µg of the "wings clipped" transposon plasmid pMiLRneo (Figure 7) and 2 µg of the helper plasmid pEF1/ILMi (Figure 5). Plasmid pEF1 does not contain the Minos transposase gene. The GFP-expressing plasmid contains the green fluorescent protein gene under the control of the CMV promoter (e.g., operably linked), but does not contain the inverted repeats of the Minos transposable element. Several controls were included (see Table 5): pMiLRneo(lin.) is the transposon plasmid pMiLRneo (Figure 6) linearized with the restriction enzyme *SacI*, cleaving the plasmid once outside the transposon; pMiLRneo(dig.) is the transposon plasmid pMiLRneo (Figure 6) digested with a combination of *SacI* and *KpnI*, cleaving the plasmid to the right and to the left of the transposon; and plasmid pMiLRneo (Figure 7) is the "wings clipped" transposon described above.

[0136] In each experiment,  $2.5 \times 10^6$  HeLa cells were used. Co-transfection with the GFP-expressing plasmid enabled an estimate to be made of the minimum fraction of cells in which the uptake of DNA had occurred. The results are shown in Table 5.



TABLE 5

| Transfection Mixture      | % of cells expressing GFP | % of cells neo <sup>R</sup> | Number of neo <sup>R</sup> colonies |
|---------------------------|---------------------------|-----------------------------|-------------------------------------|
| pMiLRneo +pEF1            | 1.55                      | 0.250                       | 6,240                               |
| pMiLRneo +EF1/ILMi        | 1.95                      | 4.118                       | 102,960                             |
| pMiLRneo(lin.) +pEF1      | 0.45                      | 0.005                       | 130                                 |
| pMiLRneo(lin.) +pEF1/ILMi | 0.63                      | 0.066                       | 1,640                               |
| pMiLRneo(dig.) +pEF1      | 0.46                      | 0.005                       | 125                                 |
| pMiLRneo(dig.) +pEF1/ILMi | 0.75                      | 0.035                       | 880                                 |
| pMiLRneo +pEF1/ILMi       | 1.60                      | 0.082                       | 2,040                               |

[0137] These results show that the enhanced integration rates observed in the presence of transposase are not the result of differential transfection efficiencies between different transfection experiments.

[0138] These results show that the highest efficiency of integration was observed in cells which had been transfected with the intact (circular) transposon (pMiLRneo) and the helper plasmid pEF1/ILMi, which encodes a Minos transposase. The results show that in these transfected cells, the transposon integrated stably in a large fraction of the cells in which uptake of DNA had occurred, which was determined by GFP detection. The fraction of cells transiently expressing GFP (1.95% maximum) likely represents an underestimate of the cells in which uptake of DNA had occurred, presumably due to the low sensitivity of GFP detection under the condition of these experiments. HeLa transfection frequencies of 10% are considered in the art to be "excellent". Taken together with these observations, the results suggest that "true" rates of integration of Minos with helper, i.e., the percent of transfected cells in which at least one copy of DNA has integrated into the genome of the cells, may be higher than 50%.

#### 4. EXON TRAPPING IN HELA CELLS

[0139] HeLa cells were co-transfected with 1 µg of the GFP-expressing plasmid pIRES/GFP (Clontech) and either (a) a mixture of 8 µg of the transposon plasmid pMiLRβgeo and 2 µg of the helper plasmid pEF1/ILMi (Figure 5); (b) a mixture of 8 µg of the transposon plasmid pMiLRβgeo and 2 µg of the plasmid pEF1; or (c) a mixture of 8 µg of pMiLRβgeo (lin.) and 2 µg of the plasmid pEF1.

[0140] The transposon plasmid pMiLRβgeo, consisting of the βgeo cassette flanked by the Minos inverted repeats, was derived from the transposon plasmid pMiLRneo (Figure 6). Specifically, the SV40neo cassette was replaced by the βgeo cassette (Friedrich and Soriano, *Genes Dev.*, 5:1513-1523 (1991)) (*Hind*III and *Eco*RI cloning sites) to produce the transposon plasmid pMiLRβgeo. The βgeo cassette contains the first intron (1690 bp), the splice acceptor site and a portion of the second exon (183 bp) of the En-2 gene (Skarnes *et al.*, *Genes Dev.*, 6:903-918 (1992); the exon is fused in-frame to an in-frame fusion consisting of the *E. coli* LacZ gene, and the neomycin resistance gene and the termination of transcription is controlled by the SV40 terminator (240 bp). The βgeo cassette is functional as an exon trap and is described in Friedrich and Soriano, *Genes Dev.*, 5:1513-1523 (1991). The neo resistance of plasmid pMiLRβgeo can only be expressed if it is integrated into an intron of an active gene, in the appropriate orientation, so that splicing produces a novel fusion protein with the neo and β-galactosidase modules at the carboxy terminus.

[0141] pMiLRβgeo (lin.) is the transposon plasmid pMiLRβgeo linearized with the restriction enzyme *Hind*III, cleaving the plasmid once within the transposon at the 5' end of the En-2 intron.

[0142] In each experiment,  $2.5 \times 10^6$  HeLa cells were used. Co-transfection with the GFP-expressing plasmid enabled an estimate to be made of the minimum fraction of cells in which the uptake of DNA had occurred. The results are shown in Table 6.

TABLE 6

| Transfection Mixture | % of cells expressing GFP | % of cells NEO <sup>R</sup> | Number of neo <sup>R</sup> colonies |
|----------------------|---------------------------|-----------------------------|-------------------------------------|
| pMiLRβgeo +pEF1      | 2.15                      | 0.002                       | 62                                  |

TABLE 6 (continued)

| Transfection Mixture  | % of cells expressing GFP | % of cells NEO <sup>R</sup> | Number of neo <sup>R</sup> colonies |
|-----------------------|---------------------------|-----------------------------|-------------------------------------|
| pMiLRβgeo +pEF1/ILMi  | 1.70                      | 0.028                       | 696                                 |
| pMiLRβgeo(lin.) +pEF1 | 0.58                      | 0.000                       | 2                                   |

[0143] In an exon trap experiment, only a small fraction of integrations, namely those in introns and in the correct orientation, are expected to express neo activity. The results show that, as expected, the frequency of neo resistant colonies was many-fold (150X) lower compared to that in the random integration experiment described in the previous section (section 4).

[0144] Twenty-two neo-resistant colonies which had been transfected with the intact (circular) transposon (pMiLRβgeo) and the helper plasmid pEF1/ILMi, which encodes a Minos transposase, were grown and analyzed histochemically for (β-galactosidase expression. Of those colonies, 16 showed detectable histochemical staining.

#### 5. MOLECULAR ANALYSIS OF TRANSPOSON INTEGRATIONS PRODUCED IN THE PRESENCE OF TRANSPOSASE

[0145] To determine the nature of the integration events, DNA from 11 neo resistant colonies transfected with the intact (circular) transposon (pMiLRneo) and the helper plasmid pEF1/ILMi (from the random integration experiment described in section 4), was analyzed by Southern blot hybridizations using several restriction enzymes and the SV40-neo cassette (see Figure 6) as a probe.

[0146] Two restriction enzyme combinations were used. The first contained *Bgl*II and *Xho*I, neither of which cut within the transposon plasmid DNA. This combination is expected to generate a single band from each integration of the transposon at different sites of the genome. The second contained the enzyme *Bgl*II, in addition to *Bgl*II and *Xho*I. *Bgl*II cleaves the transposon plasmid at three position, one within the transposon sequence and the other two in the plasmid sequences flanking the transposon, about 1.5 kb and 0.25 kb from the left and the right end of the transposon, respectively. The respective distances from the internal *Bgl*II are 2.15 kb and 1.75 kb, and these are the fragment sizes that would be detected in the Southern blots if the sequence inserted contained the original plasmid sequences that flank the Minos inverted repeats.

[0147] Restriction analysis of the transformants revealed that with *Bgl*II and *Xho*I, 6 of the colonies showed 1 band each, 3 colonies had 2 bands each, one had 3 bands and one colony had 5 bands. With the three enzymes, the number of bands in each of the colonies was doubled, and in all cases the sum of the fragment lengths were equal or smaller to the lengths of the fragments of the double digest. These results, combined together, strongly indicate that the transposon has integrated into the genome of the lines (colonies) examined in a transposase-dependent manner, i.e. without carrying any plasmid sequences.

[0148] Southern analysis was also performed on 8 neo resistant colonies transfected with the intact (circular) transposon (pMiLRβgeo) and the helper plasmid pEF1/ILMi (from the exon trap experiment described in section 5). In these experiments a combination of two enzymes was used (*Bgl*II and *Xho*I). Two fragments are expected from each independent single insertion of the transposon, because *Bgl*II cleaves within the pMiLRβgeo transposon. The results from this restriction analysis revealed that there are between two and seven insertions per line, with an average number of 3.6 insertions per line.

[0149] Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT/INVENTOR:

(A) NAME: Institute For Molecular Biology and  
Biotechnology/FORTH  
(B) STREET: Box 1527  
(C) CITY: Heraklion  
(D) STATE/PROVINCE: Crete  
(E) COUNTRY: Greece  
(F) POSTAL CODE/ZIP: 711 10

(ii) TITLE OF INVENTION: Eukaryotic Transposable Element

(iii) NUMBER OF SEQUENCES: 12

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
(B) STREET: Two Militia Drive  
(C) CITY: Lexington  
(D) STATE: Massachusetts  
(E) COUNTRY: USA  
(F) ZIP: 02421

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 09/067,755  
(B) FILING DATE: 27-APR-1998  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Carroll, Alice O.  
(B) REGISTRATION NUMBER: 33,542  
(C) REFERENCE/DOCKET NUMBER: IMBB92-01ZA3 EPO

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (781) 861-6240  
(B) TELEFAX: (781) 861-9540

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1775 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

|    |   |      |
|----|---|------|
| 5  | ACGAGCCCCA ACCACTATTA ATTCGAACAG CATGTTTTTT TTGCAGTGCG CAATGTTTAA | 60   |
|    | CACACTATAT TATCAATACT ACTAAAGATA ACACATACCA ATGCATTTCG TCTCAAAGAG | 120  |
|    | AATTTTATTC TCTTCACGAC GAAAAAAAAA GTTTTGCTCT ATTTCCAACA ACAACAAAAA | 180  |
| 10 | TATGAGTAAT TTATTCAAAC GGTTTGCTTA AGAGATAAGA AAAAAGTGAC CACTATTAAT | 240  |
|    | TCGAACGCGG CGTAAGCTTA CCTTAATCTC AAGAAGAGCA AAACAAAAGC AACTAATGTA | 300  |
|    | ACGGAATCAT TATCTAGTTA TGATCTGCAA ATAATGTCAC AATACAGCAT GCAAAAAAAT | 360  |
| 15 | TTTAGATTGC TGCAGATCAG TAGAAGTTTA GCAACGATGG TTCGTGGTAA ACCTATTTCT | 420  |
|    | AAAGAAATCA GAGTATTGAT TAGGGATTAT TTTAAATCTG GAAAGACACT TACGGAGATA | 480  |
|    | AGCAAGCAAT TAAATTTGCC TAAGTCGTCT GTGCATGGGG TGATACAAAT TTTCAAAAAA | 540  |
| 20 | AATGGGAATA TTGAAAATAA CATTCGCAAT AGAGGCCGAA CATCAGCAAT AACACCCCGC | 600  |
|    | GACAAAAGAC AACTGGCCAA AATTGTTAAG GCTGATCGTC GCCAATCTTT GAGAAATTTG | 660  |
|    | GCTTCTAAGT GGTGCGAGCA ATTGGCAAAA CTGTCAAGCG AGAGTGGACG CGACAAATTA | 720  |
| 25 | AAAAGTATTG GATATGGTTT TTATAAAGTA TGTTTTGTTA TTACCTGTGC ATCGTACCCA | 780  |
|    | ATAACTTACT CGTAATCTTA CTCGTAGGCC AAGGAAAAAC CCTTGCTTAC GCTTCGTCAA | 840  |
|    | AAAAAGAAGC GTTTGCAATG GGCTCGGGAA AGGATGTCTT GGACTCAAAG GCAATAGGAT | 900  |
| 30 | ACCATCATAT TCAGCGATGA AGCTAAATTT GATGTTAGTG TCGGCGATAC GAGAAAACGC | 960  |
|    | GTCATCCGTA AGAGGTCAGA AACATACCAT AAAGACTGCC TTAAAAGAAC AACAAAGTTT | 1020 |
|    | CCTGCGAGCA CTATGGTATG GGGATGTATG TCTGCCAAG GATTAGGAAA ACTTCATTTT  | 1080 |
| 35 | ATTGAAGGGA CAGTTAATGC TGAAAAATAT ATTAATATTT TACAAGATAG TTTGTTGCCA | 1140 |
|    | TCAATACCAA AACTATCAGA TTGCGGTGAA TTCACTTTTC AGCAGGACGG AGCATCATCG | 1200 |
|    | CACACAGCCA AGCGAACCAA AAATTGGCTG CAATATAATC AAATGGAGGT TTTAGATTGG | 1260 |
| 40 | CCATCAAATA GTCCAGATCT AAGCCCAATT GAAAATATTT GGTGGCTAAT GAAAAACCAG | 1320 |
|    | CTTCGAAATG AGCCACAAAG GAATATTTCT GACTTGAAAA TCAAGTTGCA AGAGATGTGG | 1380 |
|    | GACTCAATTT CTCAAGAGCA TTGCAAAAAT TTGTTAAGCT CAATGCCAAA ACGAGTTAAA | 1440 |
| 45 | TGCGTAATGC AGGCCAAGGG CGACGTTACA CAATTCTAAT ATTAATTAAA TTATTGTTTT | 1500 |
|    | AAGTATGATA GTAAATCACA TTACGCCGCG TTCGAATTAA TAGTGGTCAC TTTTTTCTTA | 1560 |
|    | TCTCTTAAGC AAACCGTTTG AATAAATTAC TCATATTTTT GTTGTGTTG GAAATAGAGC  | 1620 |
| 50 | AAAACTTTTT TTTTCGTCGT GAAGAGAATA AAATTCTCTT TGAGACGAAA TGCATTGGTA | 1680 |
|    | TGTGTATCT TTAGTAGTAT TGATAATATA GTGTGTTAAA CATTGCGCAC TGCAAAAAAA  | 1740 |
|    | ACATGCTGTT CGAATTAATA GTGGTTGGGG CTCGT                            | 1775 |

55

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1775 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

|            |            |            |            |             |            |      |
|------------|------------|------------|------------|-------------|------------|------|
| ACGAGCCCCA | ACCACTATTA | ATTCGAACAG | CATGTTTTTT | TTGCAGTGCG  | CAATGTTTAA | 60   |
| CACACTATAT | TATCAATACT | ACTAAAGATA | ACACATACCA | ATGCATTTTCG | TCTCAAAGAG | 120  |
| AATTTTATTC | TCTTCACGAC | GAAAAAAAAA | GTTTGTCTCT | ATTTCCAACA  | ACAACAAAAA | 180  |
| TATGAGTAAT | TTATTCAAAC | GGTTTGCTTA | AGAGATAAGA | AAAAAGTGAC  | CACTATTAAT | 240  |
| TCGAACGCGG | CGTAAGCTTA | CCTTAATCTC | AAGAAGAGCA | AAACAAAAGC  | AACTAATGTA | 300  |
| ACGGAATCAT | TATCTAGTTA | TGATCTGCAA | ATAATGTCAC | AATACAGCAT  | GCAAAAAAAT | 360  |
| TTTAGATTGC | TGCAGATCAG | TAGAAGTTTA | GCAACGATGG | TTCGTGGTAA  | ACCTATTTCT | 420  |
| AAAGAAATCA | GAGTATTGAT | TAGGGATTAT | TTTAAATCTG | GAAAGACACT  | TACGGAGATA | 480  |
| AGCAAGCAAT | TAAATTTGCC | TAAGTCGTCT | GTGCATGGGG | TGATACAAAT  | TTTCAAAAAA | 540  |
| AATGGGAATA | TTGAAAATAA | CATTGCGAAT | AGAGGCCGAA | CATCAGCAAT  | AACACCCCGC | 600  |
| GACAAAAGAC | AACTGGCCAA | AATTGTTAAG | GCTGATCGTC | GCCAATCTTT  | GAGAAATTTG | 660  |
| GCTTCTAAGT | GGTCGCAGCA | ATTGGCAAAA | CTGTCAAGCG | AGAGTGGACG  | CGACAAATTA | 720  |
| AAAAGTATTG | GATATGGTTT | TTATAAAGTA | TGTTTTGTTA | TTACCTGTGC  | ATCGTACCCA | 780  |
| ATAACTTACT | CGTAATCTTA | CTCGTAGGCC | AAGGAAAAAC | CCTTGCTTAC  | GCTTCGTCAA | 840  |
| AAAAAGAAGC | GTTTGCAATG | GGCTCGGGAA | AGGATGTCTT | GGACTCAAAG  | GCAATGGGAT | 900  |
| ACCATCATAT | TCAGCGATGA | AGCTAAATTT | GATGTTAGTG | TCGGCGATAC  | GAGAAAACGC | 960  |
| GTCATCCGTA | AGAGGTCAGA | AACATACCAT | AAAGACTGCC | TAAAAAGAAC  | AACAAAGTTT | 1020 |
| CCTGCGAGCA | CTATGGTATG | GGGATGTATG | TCTGCCAAAG | GATTAGGAAA  | ACTTCATTTC | 1080 |
| ATTGAAGGGA | CAGTTAATGC | TGAAAAATAT | ATTAATATTT | TACAAGATAG  | TTTGTTGCCA | 1140 |
| TCAATACCAA | AACTATTAGA | TTGCGGTGAA | TTCACTTTTC | AGCAGGACGG  | AGCATCATCG | 1200 |
| CACACAGCCA | AGCGAACCAA | AAATTGGCTG | CAATATAATC | AAATGGAGGT  | TTTAGATTGG | 1260 |
| CCATCAAATA | GTCCAGATCT | AAGCCCAATT | GAAAATATTT | GGTGGCTAAT  | GAAAAACCAG | 1320 |
| CTTCGAAATG | AGCCACAAAG | GAATATTTCT | GACTTGAAAA | TCAAGTTGCA  | AGAGATGTGG | 1380 |
| GACTCAATTT | CTCAAGAGCA | TTGCAAAAAT | TTGTTAAGCT | CAATGCCAAA  | ACGAGTTAAA | 1440 |

TCGGTAATGC AGGCCAAGGG CGACGTTACA CAATTCTAAT ATTAATTAAA TTATTGTTTT 1500  
 AAGTATGATA GTAAATCACA TTACGCCGCG TTCGAATTAA TAGTGGTCAC TTTTTCTTA 1560  
 5 TCTCTTAAGC AAACCGTTTG AATAAATTAC TCATATTTTT GTTGTGTGTG GAAATAGAGC 1620  
 AAAACTTTTT TTTTCGTCGT GAAGAGAATA AAATTCTCTT TGAGACGAAA TGCATTGGTA 1680  
 TGTGTTATCT TTAGTAGTAT TGATAATATA GTGTGTTAAA CATTGCGCAC TGCAAAAAAA 1740  
 10 ACATGCTGTT CGAATTAATA GTGGTTGGGG CTCGT 1775

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1775 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACGAGCCCCA ACCACTATTA ATTGCAACAG CATGTTTTTT TTGCAGTGCG CAATGTTTAA 60  
 25 CACACTATAT TATCAATACT ACTAAAGATA ACACATACCA ATGCATTTTCG TCTCAAAGAG 120  
 AATTTTATTC TCTTCACGAC GAAAAAAAAA GTTTTGCTCT ATTTCCAACA ACAACAAAAA 180  
 TATGAGTAAT TTATTCAAAC GGTTCGCTTA AGAGATAAGA AAAAAGTGAC CACTATTAAT 240  
 30 TCGAACGCGG CGTAAGCTTA CCTTAATCTC AAGAAGAGCA AAACAAAAGC AACTAATGTA 300  
 ACGGAATCAT TATCTAGTTA TGATCTGCAA ATAATGTCAC AATACAGCAT GCAAAAAAAT 360  
 TTTAGATTGC TGCAGATCAG TAGAAGTTTA GCAACGATGG TTCGTGGTAA ACCTATTTCT 420  
 35 AAAGAAATCA GAGTATTGAT TAGGGATTAT TTTAAATCTG GAAAGACACT TACGGAGATA 480  
 AGCAAGCAAT TAAATTTGCC TAAGTCGTCT GTGCATGGGG TGATACAAAT TTTCAAAAAA 540  
 AATGGGAATA TTGAAAATAA CATTGCGAAT AGAGGCCGAA CATCAGCAAT AACACCCCGC 600  
 40 GACAAAAGAC AACTGGCCAA AATTGTAAAG GCTGATCGTC GC CAATCTTT GAGAAATTTG 660  
 GCTTCTAAGT GGTGCGAGCA ATTGGCAAAA CTGTCAAGCG AGAGTGGACG CGACAAATTA 720  
 AAAAGTATTG GATATGTTTT TTATAAGTA TGTTTTGTTA TTACCTGTGC ATCGTACCCA 780  
 45 ATAACCTACT CGTAATCTTA CTCGTAGGCC AAGGAAAAAC CCTTGCTTAC GCTTCGTCAA 840  
 AAAAAGAAGC GTTTGCAATG GGCTCGGGAA AGGATGTCTT GGA CTCAAAG GCAATGGGAT 900  
 ACCATCATAT TCAGCGATGA AGCTAAATTT GATGTTAGTG TCGGCGATAC GAGAAAACGC 960  
 50 GTCATCCGTA AGAGGTCAGA AACATACCAT AAAGACTGCC TTAAGAAGAAC AACAAAGTTT 1020  
 CCTGCGAGCA CTATGGTATG GGGATGTATG TCTGCCAAAG GATTAGGAAA ACTTCATTTT 1080

5 ATTGAAGGGA CAGTTAATGC TGAAAAATAT ATTAATATTT TACAAGATAG TTTGTTGCCA 1140  
 TCAATACCAA AACTATCAGA TTGCGGTGAA TTCACTTTTC AGCAGGACGG AGCATCATCG 1200  
 10 CACACAGCCA AGCGAACCAA AAATTGGCTG CAATATAATC AAATGGAGGT TTTAGATTGG 1260  
 CCATCAAATA GTCCAGATCT AAGCCCAATT GAAAATATTT GGTGGCTAAT GAAAAACCAG 1320  
 CTCGAAATG AGCCACAAAG GAATATTTCT GACTTGAAAA TCAAGTTGCA AGAGATGTGG 1380  
 15 GA<sup>-</sup>CTCAATTT CTCAAGAGCA TTGCAAAAAT TTGTTAAGCT CAATGCCAAA ACGAGTTAAA 1440  
 TCGTAATGC AGGCCAAGGG CGACGTTACA CAATTCTAAT ATTAATTAAA TTATTGTTTT 1500  
 AAGTATGATA GTAAATCACA TTACGCCGCG TTCGAATTAA TAGTGGTCAC TTTTCTTCTTA 1560  
 20 TCTCTTAAGC AAACCGTTTG AATAAATTAC TCATATTTTT GTTGTGTTG GAAATAGAGC 1620  
 AAAACTTTTT TTTTCGTCGT GAAGAGAATA AAATTCTCTT TGAGACGAAA TGCATTGGTA 1680  
 TGTGTTATCT TTAGTAGTAT TGATAATATA GTGTGTTAAA CATTGCGCAC TGCAAAAAAA 1740  
 ACATGCTGTT CGAATTAATA GTGGTTGGGG CTCGT 1775

## (2) INFORMATION FOR SEQ ID NO:4:

25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1779 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear  
 30  
 (ii) MOLECULE TYPE: DNA (genomic)  
 (ix) FEATURE:  
 35 (A) NAME/KEY: CDS  
 (B) LOCATION: join(398..751, 812..898)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

40 ACGAGCCCCA ACCACTATTA ATTCGAACAG CATGTTTTTT TTGCAGTGCG CAATGTTTAA 60  
 CACACTATAT TATCAATACT ACTAAAGATA ACACATACCA ATGCATTTTC TCTCAAAGAG 120  
 AATTTTATTC TCTTCACGAC GAAAAAAAAA GTTTGTCTCT ATTCCAACA ACAACAAAAA 180  
 45 TATGAGTAAT TTATTCAAAC GGTTTGCTTA AGAGATAAGA AAAAAGTGAC CACTATTAAT 240  
 TCGAACGCGG CGTAAGCTTA CCTTAATCTC AAGAAGAGCA AAACAAAAGC AACTAATGTA 300  
 ACGGAATCAT TATCTAGTTA TGATCTGCAA ATAATGTCAC AATACAGCAT GCAAAAAAAT 360  
 50 TTTAGAATTG CTGCAGATCA GTAGAAGTTT AGCAACG ATG GTT CGT GGT AAA CCT 415  
 Met Val Arg Gly Lys Pro  
 1 5

55



EP 0 955 364 A2

|    |   |      |
|----|---|------|
|    | ATT TCT AAA GAA ATC AGA GTA TTG ATT AGG GAT TAT TTT AAA TCT GGA<br>Ile Ser Lys Glu Ile Arg Val Leu Ile Arg Asp Tyr Phe Lys Ser Gly<br>10 15 20    | 463  |
| 5  | AAG ACA CTT ACG GAG ATA AGC AAG CAA TTA AAT TTG CCT AAG TCG TCT<br>Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu Asn Leu Pro Lys Ser Ser<br>25 30 35    | 511  |
| 10 | GTG CAT GGG GTG ATA CAA ATT TTC AAA AAA AAT GGG AAT ATT GAA AAT<br>Val His Gly Val Ile Gln Ile Phe Lys Lys Asn Gly Asn Ile Glu Asn<br>40 45 50    | 559  |
|    | AAC ATT GCG AAT AGA GGC CGA ACA TCA GCA ATA ACA CCC CGC GAC AAA<br>Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala Ile Thr Pro Arg Asp Lys<br>55 60 65 70 | 607  |
| 15 | AGA CAA CTG GCC AAA ATT GTT AAG GCT GAT CGT CGC CAA TCT TTG AGA<br>Arg Gln Leu Ala Lys Ile Val Lys Ala Asp Arg Arg Gln Ser Leu Arg<br>75 80 85    | 655  |
| 20 | AAT TTG GCT TCT AAG TGG TCG CAG ACA ATT GGC AAA ACT GTC AAG CGA<br>Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile Gly Lys Thr Val Lys Arg<br>90 95 100   | 703  |
|    | GAG TGG ACG CGA CAG CAA TTA AAA AGT ATT GGA TAT GGT TTT TAT AAA<br>Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile Gly Tyr Gly Phe Tyr Lys<br>105 110 115 | 751  |
| 25 | GTATGTTTTG TTATTACCTG TGCATCGTAC CCAATAACTT ACTCGTAATC TTA CTCTAG   | 811  |
|    | GCC AAG GAA AAA CCC TTG CTT ACG CTT CGT CAA AAA AAG AAG CGT TTG<br>Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg Gln Lys Lys Lys Arg Leu<br>120 125 130 | 859  |
| 30 | CAA TGG GCT CGG GAA AGG ATG TCT TGG ACT CAA AGG CAA TAGGATACCA<br>Gln Trp Ala Arg Glu Arg Met Ser Trp Thr Gln Arg Gln<br>135 140 145              | 908  |
| 35 | TCATATTCAG CGATGAAGCT AAATTTGATG TTAGTGTCGG CGATACGAGA AAACGCGTCA<br>TCCGTAAGAG GTCAGAAACA TACCATAAAG ACTGCCTTAA AAGAACAACA AAGTTTCCTG            | 1028 |
|    | CGAGCACTAT GGTATGGGGA TGTATGTCTG CCAAAGGATT AGGAAAACCTT CATTTCATTG  | 1088 |
| 40 | AAGGGACAGT TAATGCTGAA AAATATATTA ATATTTTACA AGATAGTTTG TTGCCATCAA<br>TACCAAAACT ATCAGATTGC GGTGAATTCA CTTTTCAGCA GGACGGAGCA TCATCGCACA            | 1148 |
|    | CAGCCAAGCG AACCAAAAAT TGGCTGCAAT ATAATCAAAT GGAGGTTTTA GATTGGCCAT   | 1208 |
| 45 | CAATAGTCC AGATCTAAGC CCAATTGAAA ATATTGGTG GCTAATGAAA AACCAGCTTC<br>GAAATGAGCC ACAAAGGAAT ATTTCTGACT TGAAAATCAA GTTGCAAGAG ATGTGGGACT              | 1268 |
|    | CAATTTCTCA AGAGCATTGC AAAAATTTGT TAAGCTCAAT GCCAAAACGA GTTAAATGCG   | 1328 |
| 50 | TAATGCAGGC CAAGGGCGAC GTTACACAAT TCTAATATTA ATTAAATTAT TGTTTTAAGT<br>ATGATAGTAA ATCACATTAC GCCGCGTTCG AATTAATAGT GGTCACCTTTT TTCTTATCTC           | 1388 |
|    | TTAAGCAAAC CGTTTGAATA AATTACTCAT ATTTTGTGTTG TTGTTGGAAA TAGAGCAAAA  | 1448 |
| 55 |   | 1508 |
|    |   | 1568 |
|    |   | 1628 |

CTTTTTTTTT CGTCGTGAAG AGAATAAAAT TCTCTTTGAG ACGAAATGCA TTGGTATGTG 1688  
 TTATCTTTAG TAGTATTGAT AATATAGTGT GTTAAACATT GCGCACTGCA AAAAAACAT 1748  
 5 GCTGTTTCGAA TTAATAGTGG TTGGGGCTCG T 1779

## (2) INFORMATION FOR SEQ ID NO:5:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 147 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 15 (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Val Arg Gly Lys Pro Ile Ser Lys Glu Ile Arg Val Leu Ile Arg  
 1 5 10 15  
 20 Asp Tyr Phe Lys Ser Gly Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu  
 20 25 30  
 Asn Leu Pro Lys Ser Ser Val His Gly Val Ile Gln Ile Phe Lys Lys  
 35 40 45  
 25 Asn Gly Asn Ile Glu Asn Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala  
 50 55 60  
 Ile Thr Pro Arg Asp Lys Arg Gln Leu Ala Lys Ile Val Lys Ala Asp  
 65 70 75 80  
 30 Arg Arg Gln Ser Leu Arg Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile  
 85 90 95  
 Gly Lys Thr Val Lys Arg Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile  
 100 105 110  
 35 Gly Tyr Gly Phe Tyr Lys Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg  
 115 120 125  
 Gln Lys Lys Lys Arg Leu Gln Trp Ala Arg Glu Arg Met Ser Trp Thr  
 130 135 140  
 40 Gln Arg Gln  
 145

## 45 (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1779 base pairs  
 (B) TYPE: nucleic acid  
 50 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

55

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(398..751, 812..1480)

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ACGAGCCCCA ACCACTATTA ATTCGAACAG CATGTTTTTT TTGCAGTGCG CAATGTTTAA 60  
 10 CACACTATAT TATCAATACT ACTAAAGATA ACACATACCA ATGCATTTTCG TCTCAAAGAG 120  
 AATTTTATTC TCTTCACGAC GAAAAAAAAA GTTTTGCTCT ATTTCCAACA ACAACAAAAA 180  
 TATGAGTAAT TTATTCAAAC GGTTTGCTTA AGAGATAAGA AAAAAGTGAC CACTATTAAT 240  
 15 TCGAACGCGG CGTAAGCTTA CCTTAATCTC AAGAAGAGCA AAACAAAAGC AACTAATGTA 300  
 ACGGAATCAT TATCTAGTTA TGATCTGCAA ATAATGTCAC AATACAGCAT GCAAAAAAAT 360  
 TTTAGAATTG CTGCAGATCA GTAGAAGTTT AGCAACG ATG GTT CGT GGT AAA CCT 415  
 Met Val Arg Gly Lys Pro  
 1 5  
 20 ATT TCT AAA GAA ATC AGA GTA TTG ATT AGG GAT TAT TTT AAA TCT GGA 463  
 Ile Ser Lys Glu Ile Arg Val Leu Ile Arg Asp Tyr Phe Lys Ser Gly  
 10 15 20  
 25 AAG ACA CTT ACG GAG ATA AGC AAG CAA TTA AAT TTG CCT AAG TCG TCT 511  
 Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu Asn Leu Pro Lys Ser Ser  
 25 30 35  
 GTG CAT GGG GTG ATA CAA ATT TTC AAA AAA AAT GGG AAT ATT GAA AAT 559  
 Val His Gly Val Ile Gln Ile Phe Lys Lys Asn Gly Asn Ile Glu Asn  
 30 40 45 50  
 AAC ATT GCG AAT AGA GGC CGA ACA TCA GCA ATA ACA CCC CGC GAC AAA 607  
 Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala Ile Thr Pro Arg Asp Lys  
 55 60 65 70  
 35 AGA CAA CTG GCC AAA ATT GTT AAG GCT GAT CGT CGC CAA TCT TTG AGA 655  
 Arg Gln Leu Ala Lys Ile Val Lys Ala Asp Arg Arg Gln Ser Leu Arg  
 75 80 85  
 AAT TTG GCT TCT AAG TGG TCG CAG ACA ATT GGC AAA ACT GTC AAG CGA 703  
 Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile Gly Lys Thr Val Lys Arg  
 40 90 95 100  
 GAG TGG ACG CGA CAG CAA TTA AAA AGT ATT GGA TAT GGT TTT TAT AAA 751  
 Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile Gly Tyr Gly Phe Tyr Lys  
 105 110 115  
 45 GTATGTTTTG TTATTACCTG TGCATCGTAC CCAATAACTT ACTCGTAATC TTACTCGTAG 811  
 GCC AAG GAA AAA CCC TTG CTT ACG CTT CGT CAA AAA AAG AAG CGT TTG 859  
 Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg Gln Lys Lys Lys Arg Leu  
 120 125 130  
 50 CAA TGG GCT CGG GAA AGG ATG TCT TGG ACT CAA AGG CAA TGG GAT ACC 907  
 Gln Trp Ala Arg Glu Arg Met Ser Trp Thr Gln Arg Gln Trp Asp Thr  
 135 140 145 150

55

EP 0 955 364 A2

|    |  |      |
|----|--|------|
|    | ATC ATA TTC AGC GAT GAA GCT AAA TTT GAT GTT AGT GTC GGC GAT ACG    | 955  |
|    | Ile Ile Phe Ser Asp Glu Ala Lys Phe Asp Val Ser Val Gly Asp Thr    |      |
|    | 155 160 165  |      |
| 5  | AGA AAA CGC GTC ATC CGT AAG AGG TCA GAA ACA TAC CAT AAA GAC TGC    | 1003 |
|    | Arg Lys Arg Val Ile Arg Lys Arg Ser Glu Thr Tyr His Lys Asp Cys    |      |
|    | 170 175 180  |      |
| 10 | CTT AAA AGA ACA ACA AAG TTT CCT GCG AGC ACT ATG GTA TGG GGA TGT    | 1051 |
|    | Leu Lys Arg Thr Thr Lys Phe Pro Ala Ser Thr Met Val Trp Gly Cys    |      |
|    | 185 190 195  |      |
| 15 | ATG TCT GCC AAA GGA TTA GGA AAA CTT CAT TTC ATT GAA GGG ACA GTT    | 1099 |
|    | Met Ser Ala Lys Gly Leu Gly Lys Leu His Phe Ile Glu Gly Thr Val    |      |
|    | 200 205 210  |      |
| 20 | AAT GCT GAA AAA TAT ATT AAT ATT TTA CAA GAT AGT TTG TTG CCA TCA    | 1147 |
|    | Asn Ala Glu Lys Tyr Ile Asn Ile Leu Gln Asp Ser Leu Leu Pro Ser    |      |
|    | 215 220 225 230  |      |
| 25 | ATA CCA AAA CTA TTA GAT TGC GGT GAA TTC ACT TTT CAG CAG GAC GGA    | 1195 |
|    | Ile Pro Lys Leu Thr Asp Cys Gly Glu Phe Thr Phe Gln Gln Asp Gly    |      |
|    | 235 240 245  |      |
| 30 | GCA TCA TCG CAC ACA GCC AAG CGA ACC AAA AAT TGG CTG CAA TAT AAT    | 1243 |
|    | Ala Ser Ser His Thr Ala Lys Arg Thr Lys Asn Trp Leu Gln Tyr Asn    |      |
|    | 250 255 260  |      |
| 35 | CAA ATG GAG GTT TTA GAT TGG CCA TCA AAT AGT CCA GAT CTA AGC CCA    | 1291 |
|    | Gln Met Glu Val Leu Asp Trp Pro Ser Asn Ser Pro Asp Leu Ser Pro    |      |
|    | 265 270 275  |      |
| 40 | ATT GAA AAT ATT TGG TGG CTA ATG AAA AAC CAG CTT CGA AAT GAG CCA    | 1339 |
|    | Ile Glu Asn Ile Trp Trp Leu Met Lys Asn Gln Leu Arg Asn Glu Pro    |      |
|    | 280 285 290  |      |
| 45 | CAA AGG AAT ATT TCT GAC TTG AAA ATC AAG TTG CAA GAG ATG TGG GAC    | 1387 |
|    | Gln Arg Asn Ile Ser Asp Leu Lys Ile Lys Leu Gln Glu Met Trp Asp    |      |
|    | 295 300 305 310  |      |
| 50 | TCA ATT TCT CAA GAG CAT TGC AAA AAT TTG TTA AGC TCA ATG CCA AAA    | 1435 |
|    | Ser Ile Ser Gln Glu His Cys Lys Asn Leu Leu Ser Ser Met Pro Lys    |      |
|    | 315 320 325  |      |
| 55 | CGA GTT AAA TGC GTA ATG CAG GCC AAG GGC GAC GTT ACA CAA TTC        | 1480 |
|    | Arg Val Lys Cys Val Met Gln Ala Lys Gly Asp Val Thr Gln Phe        |      |
|    | 330 335 340  |      |
| 60 | TAATATTAAT TAAATTATTG TTTTAAGTAT GATAGTAAAT CACATTACGC CGCGTTCGAA  | 1540 |
|    | TTAATAGTGG TCACCTTTTTT CTTATCTCTT AAGCAAACCG TTTGAATAAA TTACTCATAT | 1600 |
|    | TTTTGTTGTT GTTGAAATA GAGCAAACT TTTTTTTTCG TCGTGAAGAG AATAAAATTC    | 1660 |
|    | TCTTTGAGAC GAAATGCATT GGTATGTGTT ATCTTTAGTA GTATTGATAA TATAGTGTGT  | 1720 |
|    | TAAACATTGC GCACTGCAAA AAAAACATGC TGTTCGAATT AATAGTGGTT GGGGCTCGT   | 1779 |

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 341 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Val Arg Gly Lys Pro Ile Ser Lys Glu Ile Arg Val Leu Ile Arg
 1           5           10           15

Asp Tyr Phe Lys Ser Gly Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu
          20           25           30

Asn Leu Pro Lys Ser Ser Val His Gly Val Ile Gln Ile Phe Lys Lys
          35           40           45

Asn Gly Asn Ile Glu Asn Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala
 50           55           60

Ile Thr Pro Arg Asp Lys Arg Gln Leu Ala Lys Ile Val Lys Ala Asp
 65           70           75           80

Arg Arg Gln Ser Leu Arg Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile
          85           90           95

Gly Lys Thr Val Lys Arg Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile
          100          105          110

Gly Tyr Gly Phe Tyr Lys Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg
          115          120          125

Gln Lys Lys Lys Arg Leu Gln Trp Ala Arg Glu Arg Met Ser Trp Thr
          130          135          140

Gln Arg Gln Trp Asp Thr Ile Ile Phe Ser Asp Glu Ala Lys Phe Asp
          145          150          155          160

Val Ser Val Gly Asp Thr Arg Lys Arg Val Ile Arg Lys Arg Ser Glu
          165          170          175

Thr Tyr His Lys Asp Cys Leu Lys Arg Thr Thr Lys Phe Pro Ala Ser
          180          185          190

Thr Met Val Trp Gly Cys Met Ser Ala Lys Gly Leu Gly Lys Leu His
          195          200          205

Phe Ile Glu Gly Thr Val Asn Ala Glu Lys Tyr Ile Asn Ile Leu Gln
          210          215          220

Asp Ser Leu Leu Pro Ser Ile Pro Lys Leu Leu Asp Cys Gly Glu Phe
          225          230          235          240

Thr Phe Gln Gln Asp Gly Ala Ser Ser His Thr Ala Lys Arg Thr Lys
          245          250          255

Asn Trp Leu Gln Tyr Asn Gln Met Glu Val Leu Asp Trp Pro Ser Asn
          260          265          270

```

# EP 0 955 364 A2

Ser Pro Asp Leu Ser Pro Ile Glu Asn Ile Trp Trp Leu Met Lys Asn  
 275 280 285  
 5 Gln Leu Arg Asn Glu Pro Gln Arg Asn Ile Ser Asp Leu Lys Ile Lys  
 290 295 300  
 Leu Gln Glu Met Trp Asp Ser Ile Ser Gln Glu His Cys Lys Asn Leu  
 305 310 315 320  
 10 Leu Ser Ser Met Pro Lys Arg Val Lys Cys Val Met Gln Ala Lys Gly  
 325 330 335  
 Asp Val Thr Gln Phe  
 340

15

## (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1779 base pairs  
 (B) TYPE: nucleic acid  
 20 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: DNA (genomic)  
 (ix) FEATURE:  
 25 (A) NAME/KEY: CDS  
 (B) LOCATION: join(398..751, 812..1480)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

30 ACGAGCCCCA ACCACTATTA ATTCGAACAG CATGTTTTTT TTGCAGTGCG CAATGTTTAA 60  
 CACACTATAT TATCAATACT ACTAAAGATA ACACATACCA ATGCATTCG TCTCAAAGAG 120  
 AATTTTATTC TCTTCACGAC GAAAAAAGAA GTTTTGCTCT ATTTCCAACA ACAACAAAAA 180  
 35 TATGAGTAAT TTATTCAAAC GGTTCGCTTA AGAGATAAGA AAAAAGTGAC CACTATTAAT 240  
 TCGAACGCGG CGTAAGCTTA CCTTAATCTC AAGAAGAGCA AAACAAAAGC AACTAATGTA 300  
 ACGGAATCAT TATCTAGTTA TGATCTGCAA ATAATGTCAC AATACAGCAT GCAAAAAAAT 360  
 40 TTTAGAATTG CTGCAGATCA GTAGAAGTTT AGCAACG ATG GTT CGT GGT AAA CCT 415  
 Met Val Arg Gly Lys Pro  
 1 5  
 ATT TCT AAA GAA ATC AGA GTA TTG ATT AGG GAT TAT TTT AAA TCT GGA 463  
 45 Ile Ser Lys Glu Ile Arg Val Leu Ile Arg Asp Tyr Phe Lys Ser Gly  
 10 15 20  
 AAG ACA CTT ACG GAG ATA AGC AAG CAA TTA AAT TTG CCT AAG TCG TCT 511  
 Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu Asn Leu Pro Lys Ser Ser  
 25 30 35  
 50 GTG CAT GGG GTG ATA CAA ATT TTC AAA AAA AAT GGG AAT ATT GAA AAT 559  
 Val His Gly Val Ile Gln Ile Phe Lys Lys Asn Gly Asn Ile Glu Asn  
 40 45 50

55

EP 0 955 364 A2

|    |   |      |
|----|---|------|
|    | AAC ATT GCG AAT AGA GGC CGA ACA TCA GCA ATA ACA CCC CGC GAC AAA   | 607  |
|    | Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala Ile Thr Pro Arg Asp Lys   |      |
|    | 55 60 65 70   |      |
| 5  | AGA CAA CTG GCC AAA ATT GTT AAG GCT GAT CGT CGC CAA TCT TTG AGA   | 655  |
|    | Arg Gln Leu Ala Lys Ile Val Lys Ala Asp Arg Arg Gln Ser Leu Arg   |      |
|    | 75 80 85  |      |
|    | AAT TTG GCT TCT AAG TGG TCG CAG ACA ATT GGC AAA ACT GTC AAG CGA   | 703  |
| 10 | Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile Gly Lys Thr Val Lys Arg   |      |
|    | 90 95 100   |      |
|    | GAG TGG ACG CGA CAG CAA TTA AAA AGT ATT GGA TAT GGT TTT TAT AAA   | 751  |
|    | Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile Gly Tyr Gly Phe Tyr Lys   |      |
|    | 105 110 115   |      |
| 15 | GTATGTTTTG TTATTACCTG TGCATCGTAC CCAATAACTT ACTCGTAATC TTACTCGTAG | 811  |
|    | GCC AAG GAA AAA CCC TTG CTT ACG CTT CGT CAA AAA AAG AAG CGT TTG   | 859  |
|    | Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg Gln Lys Lys Lys Arg Leu   |      |
|    | 120 125 130   |      |
| 20 | CAA TGG GCT CGG GAA AGG ATG TCT TGG ACT CAA AGG CAA TGG GAT ACC   | 907  |
|    | Gln Trp Ala Arg Glu Arg Met Ser Trp Thr Gln Arg Gln Trp Asp Thr   |      |
|    | 135 140 145 150   |      |
|    | ATC ATA TTC AGC GAT GAA GCT AAA TTT GAT GTT AGT GTC GGC GAT ACG   | 955  |
| 25 | Ile Ile Phe Ser Asp Glu Ala Lys Phe Asp Val Ser Val Gly Asp Thr   |      |
|    | 155 160 165   |      |
|    | AGA AAA CGC GTC ATC CGT AAG AGG TCA GAA ACA TAC CAT AAA GAC TGC   | 1003 |
|    | Arg Lys Arg Val Ile Arg Lys Arg Ser Glu Thr Tyr His Lys Asp Cys   |      |
|    | 170 175 180   |      |
| 30 | CTT AAA AGA ACA ACA AAG TTT CCT GCG AGC ACT ATG GTA TGG GGA TGT   | 1051 |
|    | Leu Lys Arg Thr Thr Lys Phe Pro Ala Ser Thr Met Val Trp Gly Cys   |      |
|    | 185 190 195   |      |
|    | ATG TCT GCC AAA GGA TTA GGA AAA CTT CAT TTC ATT GAA GGG ACA GTT   | 1099 |
| 35 | Met Ser Ala Lys Gly Leu Gly Lys Leu His Phe Ile Glu Gly Thr Val   |      |
|    | 200 205 210   |      |
|    | AAT GCT GAA AAA TAT ATT AAT ATT TTA CAA GAT AGT TTG TTG CCA TCA   | 1147 |
|    | Asn Ala Glu Lys Tyr Ile Asn Ile Leu Gln Asp Ser Leu Leu Pro Ser   |      |
|    | 215 220 225 230   |      |
| 40 | ATA CCA AAA CTA TCA GAT TGC GGT GAA TTC ACT TTT CAG CAG GAC GGA   | 1195 |
|    | Ile Pro Lys Leu Ser Asp Cys Gly Glu Phe Thr Phe Gln Gln Asp Gly   |      |
|    | 235 240 245   |      |
|    | GCA TCA TCG CAC ACA GCC AAG CGA ACC AAA AAT TGG CTG CAA TAT AAT   | 1243 |
| 45 | Ala Ser Ser His Thr Ala Lys Arg Thr Lys Asn Trp Leu Gln Tyr Asn   |      |
|    | 250 255 260   |      |
|    | CAA ATG GAG GTT TTA GAT TGG CCA TCA AAT AGT CCA GAT CTA AGC CCA   | 1291 |
|    | Gln Met Glu Val Leu Asp Trp Pro Ser Asn Ser Pro Asp Leu Ser Pro   |      |
|    | 265 270 275   |      |
| 50 | ATT GAA AAT ATT TGG TGG CTA ATG AAA AAC CAG CTT CGA AAT GAG CCA   | 1339 |
|    | Ile Glu Asn Ile Trp Trp Leu Met Lys Asn Gln Leu Arg Asn Glu Pro   |      |
|    | 280 285 290   |      |

55



CAA AGG AAT ATT TCT GAC TTG AAA ATC AAG TTG CAA GAG ATG TGG GAC 1387  
 Gln Arg Asn Ile Ser Asp Leu Lys Ile Lys Leu Gln Glu Met Trp Asp  
 295 300 305 310

5 TCA ATT TCT CAA GAG CAT TGC AAA AAT TTG TTA AGC TCA ATG CCA AAA 1435  
 Ser Ile Ser Gln Glu His Cys Lys Asn Leu Leu Ser Ser Met Pro Lys  
 315 320 325

CGA GTT AAA TGC GTA ATG CAG GCC AAG GGC GAC GTT ACA CAA TTC 1480  
 Arg\_Val Lys Cys Val Met Gln Ala Lys Gly Asp Val Thr Gln Phe  
 10 330 335 340

TAATATTAAT TAAATTATG TTTTAAGTAT GATAGTAAAT CACATTACGC CGCGTTCGAA 1540  
 TTAATAGTGG TCACCTTTTTT CTTATCTCTT AAGCAAACCG TTTGAATAAA TTACTCATAT 1600  
 15 TTTTGTGTGTT GTTGGAATA GAGCAAACT TTTTTCG TCGTGAAGAG AATAAAATTC 1660  
 TCTTTGAGAC GAAATGCATT GGTATGTGTT ATCTTAGTA GTATTGATAA TATAGTGTGT 1720  
 TAAACATTGC GCACTGCAAA AAAACATGC TGTTCAATT AATAGTGGTT GGGGCTCGT 1779

20 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 341 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Val Arg Gly Lys Pro Ile Ser Lys Glu Ile Arg Val Leu Ile Arg  
 1 5 10 15  
 30 Asp Tyr Phe Lys Ser Gly Lys Thr Leu Thr Glu Ile Ser Lys Gln Leu  
 20 25 30  
 Asn Leu Pro Lys Ser Ser Val His Gly Val Ile Gln Ile Phe Lys Lys  
 35 35 40 45  
 Asn Gly Asn Ile Glu Asn Asn Ile Ala Asn Arg Gly Arg Thr Ser Ala  
 50 55 60  
 Ile Thr Pro Arg Asp Lys Arg Gln Leu Ala Lys Ile Val Lys Ala Asp  
 65 70 75 80  
 40 Arg Arg Gln Ser Leu Arg Asn Leu Ala Ser Lys Trp Ser Gln Thr Ile  
 85 90 95  
 Gly Lys Thr Val Lys Arg Glu Trp Thr Arg Gln Gln Leu Lys Ser Ile  
 100 105 110  
 45 Gly Tyr Gly Phe Tyr Lys Ala Lys Glu Lys Pro Leu Leu Thr Leu Arg  
 115 120 125  
 Gln Lys Lys Lys Arg Leu Gln Trp Ala Arg Glu Arg Met Ser Trp Thr  
 130 135 140  
 50 Gln Arg Gln Trp Asp Thr Ile Ile Phe Ser Asp Glu Ala Lys Phe Asp  
 145 150 155 160

55

EP 0 955 364 A2

Val Ser Val Gly Asp Thr Arg Lys Arg Val Ile Arg Lys Arg Ser Glu  
165 170 175

5 Thr Tyr His Lys Asp Cys Leu Lys Arg Thr Thr Lys Phe Pro Ala Ser  
180 185 190

Thr Met Val Trp Gly Cys Met Ser Ala Lys Gly Leu Gly Lys Leu His  
195 200 205

10 Phe Ile Glu Gly Thr Val Asn Ala Glu Lys Tyr Ile Asn Ile Leu Gln  
210 215 220

Asp Ser Leu Leu Pro Ser Ile Pro Lys Leu Ser Asp Cys Gly Glu Phe  
225 230 235 240

15 Thr Phe Gln Gln Asp Gly Ala Ser Ser His Thr Ala Lys Arg Thr Lys  
245 250 255

Asn Trp Leu Gln Tyr Asn Gln Met Glu Val Leu Asp Trp Pro Ser Asn  
260 265 270

20 Ser Pro Asp Leu Ser Pro Ile Glu Asn Ile Trp Trp Leu Met Lys Asn  
275 280 285

Gln Leu Arg Asn Glu Pro Gln Arg Asn Ile Ser Asp Leu Lys Ile Lys  
290 295 300

25 Leu Gln Glu Met Trp Asp Ser Ile Ser Gln Glu His Cys Lys Asn Leu  
305 310 315 320

Leu Ser Ser Met Pro Lys Arg Val Lys Cys Val Met Gln Ala Lys Gly  
325 330 335

30 Asp Val Thr Gln Phe  
340

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Val Trp Gly Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

5 Trp Pro Ser Gln Ser Pro Asp Leu  
1 5

(2) INFORMATION FOR SEQ ID NO:12:

10 (i) SEQUENCE CHARACTERISTICS:  
- (A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

20 Trp Pro Ser Asn Ser Pro Asp Leu  
1 5

25

## Claims

1. A method for inducing a mutation in a cell, comprising the steps of:

30 a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; and  
b) introducing the isolated transposable element of step a) into the cell in the presence of:

35 i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or  
ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, optionally wherein the transposable element is modified to include a promoter operably linked to an indicator gene under the control of said promoter flanked by the inverted terminal repeats of the isolated transposable element and/or the  
40 transposable element and nucleic acid sequence encoding the transposase protein are incorporated into a viral vector.

2. A method for isolating a gene of interest in a cell which includes a mutation, comprising the steps of:

45 a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include a promoter operably linked to an indicator gene under the control of said promoter flanked by the inverted terminal repeats of the isolated transposable element;  
b) introducing the isolated transposable element of step a) into a population of cells in the presence of:

50 i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or  
ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, thereby producing a sample;  
55

c) detecting expression of the indicator gene in the sample obtained in step b), thereby identifying cells in which the transposable element has integrated into the genome of the cells;

d) selecting from among the cells identified in step c) cells which have a mutation in a gene of interest; and  
 e) isolating the gene of interest which includes the mutation from the cells identified in step d), optionally : (a) wherein the indicator gene is a selected from the group consisting of:

- a) a selectable marker gene; and
- b) a reporter gene, and/or (b) wherein the transposable element and nucleic acid sequence encoding the transposase protein are incorporated into a viral vector; and/or (c) wherein the cell is an animal somatic or germ line cell.

3. A method for selecting an insertional mutation in a gene in a cell, comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, the isolated transposable element being modified to include a minimal promoter operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element;

b) introducing the isolated transposable element of step a) into a population of cells in the presence of:

- i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or
- ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, thereby producing a sample;

c) detecting expression of the indicator gene in the sample obtained in step b), thereby identifying cells in which the transposable element has integrated near or within a gene; and

d) isolating from the cells identified in step c) the gene in which the transposable element has integrated near or within, optionally : (a) wherein the minimal promoter is a TATA box; and/or (b) wherein the transposable element and nucleic acid sequence encoding the transposase protein are incorporated into a viral vector; and/or (c) wherein the cell is an animal somatic or germ line cell.

4. A method for selecting an insertional mutation in a gene in a cell, comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include a splice acceptor site operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element;

b) introducing the isolated transposable element of step a) into a population of cells in the presence of:

- i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or
- ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, thereby producing a sample;

c) detecting expression of the indicator gene in the sample obtained in step b), thereby identifying cells in which the transposable element has integrated near or within a gene; and

d) isolating from the cells identified in step c) the gene in which the transposable element has integrated near or within, optionally : (a) wherein the transposable element and nucleic acid sequence encoding the transposase protein are incorporated into a viral vector, wherein the cell is an animal somatic or germ line cell.

5. A method for reversing a mutation in a gene of interest, obtained according to the method of Claim 2, comprising introducing into cells identified in step d):

- i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or
- ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, optionally : (a) wherein the nucleic acid sequence encoding the transposase protein is incorporated into a viral vector, and/or (b) wherein the cells

are animal somatic or germ line cells.

6. A method for reversing a mutation in a gene, obtained according to the method of Claim 3, comprising introducing into cells identified in step c):

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or  
 ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, optionally : (a) wherein the nucleic acid sequence encoding the transposase protein is incorporated into a viral vector; and/or (b) wherein the cells are animal somatic or germ line cells.

7. A method for reversing a mutation in a gene, obtained according to the method of Claim 4, comprising introducing into cells identified in step c):

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or  
 ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; optionally : (a) wherein the nucleic acid sequence encoding the transposase protein is incorporated into a viral vector; and/or (b) wherein the cells are animal somatic or germ line cells.

8. A method for introducing a reversible mutation in a gene of interest in a cell, comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include:

i) a promoter operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element; or  
 ii) a minimal promoter operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element; or  
 iii) a splice acceptor site operably linked to an indicator gene flanked by the inverted terminal repeats of the isolated transposable element;

b) introducing the isolated transposable element of step a) into a gene of interest, thereby producing a mutated gene;

c) introducing the mutated gene of step b) into a population of cells under conditions sufficient for homologous recombination between the mutated gene and the corresponding endogenous gene, thereby producing a sample; and

d) selecting from the sample obtained in step c) cells in which the endogenous gene has been replaced the mutated gene, optionally : (a) wherein the indicator gene is selected from the group consisting of:

a) a reporter gene; and  
 b) a selectable marker gene; and/or (b) wherein the minimal promoter is a TATA box; and/or (c) wherein the transposable element is incorporated into a viral vector; and/or (d) wherein the cell is an animal somatic or germ line cell.

9. A method for reversing a mutation in a gene, obtained according to the method of Claim 8, comprising introducing into cells identified in step d):

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or  
 ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, optionally : (a) wherein the nucleic acid sequence encoding the transposase protein is incorporated into a viral vector; and/or (b) wherein the cells are animal somatic or germ line cells.

10. A method for inducing loss of a nucleic acid sequence of interest which was integrated into the chromosome of a

cell according to a method comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the inverted terminal repeats of the isolated transposable element; and

b) introducing the isolated transposable element of step a) into the cell in the presence of:

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or

ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, thereby producing a cell comprising the nucleic acid sequence of interest integrated into its chromosome,

wherein said method comprises introducing into the cell comprising the nucleic acid sequence of interest integrated into its chromosome:

1) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or

2) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, optionally : (a) wherein the nucleic acid sequence encoding the transposase protein is incorporated into a viral vector; and/or (b) wherein the cells are animal somatic or germ line cells; wherein the cells are somatic or germ line cells of a transgenic animal; and/or (d) wherein the isolated transposable element is modified to include the gene of interest operably linked to a promoter and an indicator gene under the control of said promoter.

#### 11. A method of producing a transgenic plant, comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the inverted terminal repeats of the isolated transposable element; b) introducing the isolated transposable element of step a) into a plant cell in the presence of:

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; or

ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4; and

c) cultivating the transformed plant cell obtained in step b) under conditions appropriate for regeneration of a plant, thereby producing the transgenic plant, optionally : (a) wherein the nucleic acid sequence of interest encodes a protein of interest; and/or (b) wherein the isolated transposable element is modified to include the nucleic acid sequence of interest operably linked to a promoter and an indicator gene under the control of said promoter; and/or (c) wherein the nucleic acid sequence of interest is selected from the group consisting of:

a) a reporter gene; and

b) a selectable marker gene; and/or (d) wherein the transposable element and the nucleic acid sequence encoding the transposase protein are incorporated into a viral vector.

#### 12. A method of producing a transgenic animal and progeny thereof, comprising the steps of:

a) providing an isolated transposable element having a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the inverted terminal repeats of the isolated transposable element; and

b) introducing the isolated transposable element of step a) into a germ line cell of an animal in the presence of:

i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or

ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, optionally : (a) wherein the nucleic sequence of interest encodes a protein of interest; and/or (b) wherein the isolated transposable element is modified to include the nucleic acid sequence of interest operably linked to a promoter and an indicator gene under the control of said promoter; and/or (c) wherein the nucleic acid sequence of interest is selected from the group consisting of:

- a) a reporter gene; and
- b) a selectable marker gene; and/or (d) wherein the transposable element and the nucleic acid sequence encoding the transposase protein are incorporated into a viral vector.

13. A method for integrating a nucleic acid sequence of interest into the chromosome of a cell, comprising the steps of:

- a) providing an isolated transposable element having a nucleic sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4, the isolated transposable element being modified to include the nucleic acid sequence of interest flanked by the inverted terminal repeats of the isolated transposable element; and
- b) introducing the isolated transposable element of step a) into the cell in the presence of:

- i) a transposase protein encoded by a nucleic acid sequence which hybridizes to the DNA sequence of SEQ ID NO: 1 or SEQ ID NO:4; or
- ii) a nucleic acid sequence encoding a transposase protein, the nucleic acid sequence characterized by the ability to hybridize to the DNA sequence of SEQ ID NO:1 or SEQ ID NO:4, thereby producing a sample; optionally : (a) further comprising selecting from the sample obtained in step b) cells in which the transposable element has integrated into the chromosome; and/or (b) wherein the nucleic acid sequence encoding the transposase protein is integrated into the genome of the cell prior to the transposable element containing the nucleic acid sequence of interest; and/or (c) wherein the cell is an animal somatic or germ line cell; and/or (d) wherein the nucleic acid sequence of interest encodes a protein of interest, and/or (e) wherein the isolated transposable element is modified to include the nucleic acid sequence of interest operably linked to a promoter and an indicator gene under the control of said promoter (wherein for example the indicator gene is selected from the group consisting of:

- a) a reporter gene; and
- b) a selectable marker gene) ; and/or (f) wherein the nucleic acid sequence of interest is selected from the group consisting of:

- a) a reporter gene; and
- b) a selectable marker gene; and/or (g) wherein the transposable element and the nucleic acid sequence encoding the transposase protein are incorporated into a viral vector.

acgagccccaaccactattaatcgaacagcatgtttttttgagtcgcaatgttttaa 60  
 cacactatattatcaataactactaaagataaacacataccaatgcatttcgtctcaaagag 120  
 aatttttattctcttcacgacgaaaaaaagtgttgcctctatttcccaacaacaacaaaaa 180  
 tatgagtaaatatttcaaacggtttgcttaagagataagaaaaaagtgaccactattaat 240  
 tcgaacgcggcgtaagCTTACCTTAATCTCAAGAAGACCAAAACAAAGCAACTAATGTA 300  
 M S Q Y S M Q K N  
 ACGGAATCATTATCTAGTTATGATCTGCAAATAATGTCACAATACAGCATGCAAAAAAT 360  
 F R L L Q I S R S L A T M V R G K P I S 8  
 TTTAGATTGCTGCAGATCAGTAGAAGTTTAGCAACGATGGTTCGTGGTAAACCTATTCT 420  
 K E I R V L I R D Y F K S G K T L T E I 28  
 AAAGAAATCAGAGTATTGATTAGGGATTATTTAAATCTGGAAGACACTTACGGAGATA 480  
 S K Q L N L P K S S V H G V I Q I F K K 48  
 AGCAAGCAATTAAATTTGCCTAAGTCGTCGTGCATGGGGTGATACAAATTTTCAAAAAA 540  
 N G N I E N N I A N R G R T S A I T P R 68  
 AATGGGAATATTGAAAAATAACATTGCCAATAGAGCCCGACATCAGCAATAACACCCCGC 600  
 D K R Q L A K I V K A D R R Q S L R N L 88  
 GACAAAAGACAACTGGCCAAAATTTTAAGGCTGATCGTCGCCAATCTTTGAGAAATTTG 660  
 A S K W S Q Q L A K L S S E S G R D K L 108  
 GCTTCTAAGTGGTTCGAGCAATTTGGCAAAACTGTCAAGCGAGAGTGACGCGACAAATTA 720

FIG. 1A



K S I G Y G F Y K 118  
 AAAAGTATTGGATATGGTTTTTATATAAagtatgttttattacacctgtgcacgtaccca 780  
 ataacttactcgtaatcttactcgtagGCCAAGGAAAAACCCCTTGCTTACGCTTCGTCAA 128  
 A K E K P L L L R 840  
 \*  
 K K K R L Q W A R E R M S W T Q R Q W D 148  
 AAAAAGAAAGCGTTTGTCAATGGGCTCGGGAAGGATGTCTTGGACTCAAAGGCAATGGGAT 900  
 A  
 T I I F S D E A K F D V S V G D T R K R 168  
 ACCATCATATTCAGCGATGAAGCTAAATTGTGATGTGTGCGCGATACGAGAAAAACGC 960  
 V I R K R S E T Y H K D C L K R T T K F 188  
 GTCATCCGTAAGAGGTCAGAAAAACATACCAATAAAGACTGCCTTAAAGAACAACAAGTTT 1020  
 P A S T M V W G C M S A K G L G K L H F 208  
 CCTGCGAGCACTATGGTATGGGGATGTATGTCTGCCAAAGGATTAGGAAAACTTCATTTC 1080  
 I E G T V N A E K Y I N I L Q D S L L P 228  
 ATTGAAGGCACAGTTAATGCTGAAAAATATATTAATATTTTACAAGATAGTTTGTGCCA 1140  
 L  
 S I P K L S D C G E F T F Q Q D G A S S 248  
 TCAATACCAAACTATCAGATTGCGGTGAATTCACCTTTTCAGCAGGACGGAGCATCATCG 1200  
 T  
 H T A K R T K N W L Q Y N Q M E V L D W 268  
 CACACAGCCAGCGAACCAAAATTTGGCTGCAATATAATCAAAATGGAGGTTTAGATTGG 1260

FIG. 1B

P S N S P D L S P I E N I W L M K N Q 288  
 CCATCAATAGTCCAGATCTAAGCCCAATTGAAATATTTGGTGGCTAATGAAAAACCAG 1320  
  
 L R N E P Q R N I S D L K I K L Q E M W 308  
 CTTCGAAATGAGCCACAAGGAATATTTCTGACTTGAAAAATCAAGTTGCAAGAGATGTGG 1380  
  
 D S I S Q E H C K N L L S S M P K R V K 328  
 GACTCAATTTCTCAAGAGCATTGCAAAAAATTTGTTAAGCTCAATGCCAAAAACGAGTTAAA 1440  
  
 C V M Q A K G D V T Q F 341  
 TGCGTAATGCAGGCCAAGGGCGACGTTACACAATTCTAATATTAATAATTATTGTTTT 1500  
  
 AAGTATGATAGTAAATCACAttacgcgcgttcgaattaataatagtggtcacttttttctta 1560  
 tctcttaagcaaacggtttgaataaaattactcataatttttgtgtgttggaataagagc 1620  
 aaaaacttttttttcgtcgtgaagagaataaaattctctttgagacgaaatgcattggta 1680  
 tgtgttatctttagtagtattgataataatagtggtttaaacattgcgcactgcacaaaaaa 1740  
 acatgctgttcgaattaatagtggttggtggtcgt 1775

FIG. 1C

```

acgagccccaaccactattaatcgaacagcatgtttttttgcaagtgcgcaatgtttaa      60
cacactatattatcaataactactaaagataacacataccaatgcatttcgtctcaaaagag    120
aattttattctcttcacgacgaaaaaaagtttgctctatttccaaacaacaacaaaaa      180
tatgagtaaatatttattcaaacggttgcttaagagataaagaaaaaagtgaccactattaat    240
tcgaaacgcgcgtaagCTTACCTTAATCTCAAGAGAGCAAAACAAAGCAACTAATGTA      300
ACGGAATCATTAATCTAGTTATGATCTGCAATAATGTCACAATACAGCATGCAAAAAAAT      360

      M V R G K P I S
TTTAGAATTGCTGCAGATCAGTAGAAGTTTAGCAACGATGGTTCGTGGTAACCTATTTC      420
K E I R V L I R D Y F K S G K T L T E I      28
TAAAGAAATCAGAGTATTGATTAGGGATTATTTAAATCTGGAAAGACACTTACGGAGAT      480
S K Q L N L P K S S V H G V I Q I F K K      48
AAGCAAGCAATTAAATTTGCCCTAAGTCGTCGTGATGGGTGATACAAATTTTCAAAAAA      540
N G N I E N N I A N R G R T S A I T P R      68
AAATGGGAATATTGAAAAATAACATTGCGAATAGAGGCCGGAACATCAGCAATAACACCCCG      600
D K R Q L A K I V K A D R R Q S L R N L      88
CGACAAAAGACAACCTGGCCAAAATTTAAGGCTGATCGTCGCCAATCTTTGAGAAATTT      660
A S K W S Q T I G K T V K R E W T R Q Q      108
GGCTTCTAAGTGGTCGACAGACAATTGGCAAACTGTCAAGCGAGAGTGGACGCGACAGCA      720

```

FIG. 2A

L K S I G Y G F Y K 118  
 ATTAAAAAGTATTGGATATGGTTTTTTATAAAGtatgttttggttattacctgtgcacgta 780  
  
 cccaataaacttactcgtaatcttactcgtagGCCAAGGAAAAACCCCTTGCTTACGCTTCG 128  
 A K E K P L L T L R 840  
  
 \*  
 Q K K K R L Q W A R E R M S W T Q R Q W 148  
 TCAAAAAAAGAGCGTTTGCAATGGGCTCGGGAAGGATGTCTTGGA CTCAAAGGCAATG 900  
 A  
  
 D T I I F S D E A K F D V S V G D T R K 168  
 GGATACCATCATATTCAGCGATGAAGCTAAATTTGATGTGTAGTGTGCGCGATACGAGAAA 960  
  
 R V I R K R S E T Y H K D C L K R T T K 188  
 ACGGTCATCCGTAAGAGGTCAGAAACATACCATAAAGACTGCCTTAAAAGAACACAAA 1020  
  
 F P A S T M V W G C M S A K G L G K L H 208  
 GTTTCCTGCGAGGACTATGGTATGGGATGTATGTCTGCCAAAGGATTAGGAAAACTTCA 1080  
  
 F I E G T V N A E K Y I N I L Q D S L L 228  
 TTTCAATTGAAGGGACAGTTAATGCTGAAAAATATATTAATTTTACAAGATAGTTTGT 1140  
  
 L  
 P S I P K L S D C G E F T F Q Q D G A S 248  
 GCCATCAATACCAAACTATCAGATTGCGGTGAATTCACTTTTCAGCAGGACGGAGCATC 1200  
  
 T  
  
 S H T A K R T K N W L Q Y N Q M E V L D 268  
 ATGCACACAGCCAAAGCCAAACCAAAATTTGGCTGCAATATAATCAAAATGGAGGTTTAGA 1260

FIG. 2B

W P S N S P D L S P I E N I W L M K N 288  
 TTGGCCATCAAATAGTCCAGATCTAAGCCCAATTGAAATATTTGGTGGCTAATGAAAAA 1320  
  
 Q L R N E P Q R N I S D L K I K L Q E M 308  
 CCAGCTTCGAAATGAGCCCAAAGGAATATTTCTGACTTGAAAAATCAAGTTGCAAGAGAT 1380  
  
 W D S I S Q E H C K N L L S S M P K R V 328  
 GTGGGACTCAATTTCTCAAGAGCATTGCAAAAATTTGTTAAGCTCAATGCCCAAAACGAGT 1440  
  
 K C V M Q A K G D V T Q F 341  
 TAAATGCGTAATGCAGGCCAAGGGCGACGTTACACAAATTCCTAATATTAATTAATTATTG 1500  
  
 TTTTAAGTATGATAGTAAATCACattacgcgcggttcgaattaatagtggtcactttttt 1560  
  
 cttatctttaagcaaacggtttgaataaaattactcataatttttgtgtgttggaata 1620  
  
 gagcaaaacttttttttcgtcgtgaagagaataaaaattctcttttgagacgaaatgcatt 1680  
  
 ggatgtgttatcttttagtagtattgataatatagtggtttaaacattgcgccactgcaaa 1740  
  
 aaaaacatgctgttcgaattaatagtggttggtgggctcgt 1779

FIG. 2C




FIG. 3A




FIG. 3B




FIG. 4

### pEF-1/ILMi - The helper plasmid




Figure 5

### pMiLRneo - The transposon plasmid




Figure 6



### pMiLneo - The "wings clipped" plasmid





Figure 7



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 955 364 A3**

(12)

## EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
26.09.2001 Bulletin 2001/39

(51) Int Cl.7: **C12N 15/12, C12N 15/10,  
C12N 15/90, C07K 14/435**

(43) Date of publication A2:  
10.11.1999 Bulletin 1999/45

(21) Application number: **98309554.8**

(22) Date of filing: **23.11.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

- **Franz, Gerald H.**  
2500 Baden (AT)
- **Loukeris, Athanasios**  
Heidelberg (DE)
- **Klinakis, Apostolos G.**  
71500 Gazl, Heraklion (Crete) (GR)

(30) Priority: **27.04.1998 US 67755**

(71) Applicant: **INSTITUTE FOR MOLECULAR  
BIOLOGY AND BIOTECHNOLOGY/FORTH  
GR-711 10 Heraklion (GR)**

(74) Representative: **Maschio, Antonio et al**  
**D Young & Co,**  
**21 New Fetter Lane**  
**London EC4A 1DA (GB)**

(72) Inventors:  
• **Savakis, Charalambos**  
**Heraklion 700 13, Crete (GR)**

(54) **Eukaryotic transposable element**

(57) Disclosed are isolated transposable elements, isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein), a purified transposase protein, or peptide fragments thereof, encoded by the DNA sequences. The isolated transposase

elements and the isolated DNA sequences are characterized by the ability to hybridize to the DNA sequence of Minos-1. Further disclosed are methods of gene tagging, insertional mutagenesis and exon trapping. Transgenic animals and transgenic plants are also disclosed.

**EP 0 955 364 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 9554

| DOCUMENTS CONSIDERED TO BE RELEVANT   |   |   |  |
|---|---|---|--|
| Category  | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim                                       | CLASSIFICATION OF THE APPLICATION (Int.CI.6)         |
| X   | LOUKERIS T G ET AL: "GENE TRANSFER INTO THE MEDFLY, CERATITIS CAPITATA, WITH A DROSOPHILA HYDEI TRANSPOSABLE ELEMENT" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 270, no. 5244, 22 December 1995 (1995-12-22), pages 2002-2005, XP000941764 ISSN: 0036-8075<br>* page 2003, left-hand column - middle column *<br>* page 2004; figure 3A *<br>* the whole document *  | 1, 12, 13   | C12N15/12<br>C12N15/10<br>C12N15/90<br>C07K14/435    |
| Y   | ---   | 2-10  |  |
| X   | US 5 348 874 A (SAVAKIS CHARALAMBOS ET AL) 20 September 1994 (1994-09-20)<br>* column 9, line 46 - column 11, line 29 *<br>* claim 7 *  | 1, 10, 12, 13   |  |
| X   | LOUKERIS T G ET AL: "Introduction of the transposable element Mimos into the germline of Drosophila melanogaster" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, October 1995 (1995-10), pages 9485-9489, XP002163150 ISSN: 0027-8424<br>* page 9488, right-hand column, last paragraph - page 9489, right-hand column, line 2 *<br>* page 9488, line 11 - line 23; figure 4 * | 1, 10, 12, 13   | TECHNICAL FIELDS SEARCHED (Int.CI.6)<br>C12N<br>C07K |
| Y   | ---   | 2, 3  |  |
|   | ---   |   |  |
| The present search report has been drawn up for all claims  |   |   |  |
| Place of search<br><b>THE HAGUE</b>   |   | Date of completion of the search<br><b>23 July 2001</b> | Examiner<br><b>Schmitz, T</b>                        |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone<br/>Y : particularly relevant if combined with another document of the same category<br/>A : technological background<br/>O : non-written disclosure<br/>P : intermediate document</p> <p>T : theory or principle underlying the invention<br/>E : earlier patent document, but published on, or after the filing date<br/>D : document cited in the application<br/>L : document cited for other reasons<br/>&amp; : member of the same patent family, corresponding document</p> |   |   |  |

EPO FORM 1503 (USE 1/92) (P04021)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 9554

| DOCUMENTS CONSIDERED TO BE RELEVANT  |  |   |  |
|--|--|---|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim                                       | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
| Y  | ARCA B ET AL: "MOBILIZATION OF A MINOS TRANSPOSON IN DROSOPHILA MELANOGASTER CHROMOSOMES AND CHROMATID REPAIR BY HETERODUPLEX FORMATION" GENETICS, GENETICS SOCIETY OF AMERICA, AUSTIN, TX, US, vol. 145, no. 2, February 1997 (1997-02), pages 267-279, XP000990922 ISSN: 0016-6731<br>* abstract * | 5-10  |  |
| Y  | NUSSAUME L ET AL: "Analysis of splice donor and acceptor site function in a transposable gene trap derived from the maize element Activator." MOLECULAR & GENERAL GENETICS, vol. 249, no. 1, 1995, pages 91-101, XP002172067 ISSN: 0026-8925<br>* abstract *   | 4,8,9   |  |
| Y  | SEIFERT H S ET AL: "SHUTTLE MUTAGENESIS A METHOD OF TRANSPOSON MUTAGENESIS FOR SACCHAROMYCES-CEREVISIAE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 83, no. 3, 1986, pages 735-739, XP002171787 1986 ISSN: 0027-8424<br>* abstract *                                 | 8,9   |  |
| The present search report has been drawn up for all claims   |  |   | TECHNICAL FIELDS SEARCHED (Int.Cl.8)         |
| Place of search<br><b>THE HAGUE</b>  |  | Date of completion of the search<br><b>23 July 2001</b> | Examiner<br><b>Schmitz, T</b>                |
| <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone<br/> Y : particularly relevant if combined with another document of the same category<br/> A : technological background<br/> O : non-written disclosure<br/> P : intermediate document</p> <p>I : theory or principle underlying the invention<br/> E : earlier patent document, but published on, or after the filing date<br/> O : document cited in the application<br/> L : document cited for other reasons<br/> &amp; : member of the same patent family, corresponding document</p> |  |   |  |

EP Form 1503 03/82 (Pct/Ent)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 9554

| DOCUMENTS CONSIDERED TO BE RELEVANT   |  |  |   |
|---|--|--|---|
| Category  | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim  | CLASSIFICATION OF THE APPLICATION (Int.Cl.6)    |
| A   | <p>DATABASE EMBL SEQUENCE DATABASE 'Online! HINXTON, GB;<br/>Accession number: X61695,<br/>12 September 1991 (1991-09-12)<br/>FRANZ G., SAVAKIS C.: "Minos, a new transposable element for Drosophila hydei, is a member of the TC1-like family of transposons"<br/>XP002172806<br/>* abstract *<br/>-&amp; FRANZ G, SAVAKIS C: "Minos, a new transposable element from Drosophila hydei, is a member of the Tc1-like family of transposons"<br/>NUCLEIC ACID RESEARCH,<br/>vol. 19, no. 23, 1991, page 6646<br/>XP002172805</p> |  |   |
| A   | <p>FRANZ GERALD ET AL: "Mobile Minos elements from Drosophila hydei encode a two-exon transposase with similarity to the paired DNA-binding domain."<br/>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,<br/>vol. 91, no. 11, 1994, pages 4746-4750,<br/>XP002171786<br/>1994<br/>ISSN: 0027-8424<br/>* abstract *</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>  |  | <p>TECHNICAL FIELDS<br/>SEARCHED (Int.Cl.6)</p> |
| The present search report has been drawn up for all claims  |  |  |   |
| Place of search<br><b>THE HAGUE</b>   |  | Date of completion of the search<br><b>23 July 2001</b>  | Examiner<br><b>Schmitz, T</b>                   |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone<br/>Y : particularly relevant if combined with another document of the same category<br/>A : technological background<br/>O : non-written disclosure<br/>P : intermediate document</p> |  | <p>T : theory or principle underlying the invention<br/>E : earlier patent document, but published on or after the filing date<br/>U : document cited in the application<br/>L : document cited for other reasons<br/>&amp; : member of the same patent family, corresponding document</p> |   |

EPO FORM 1503 (3/92) (P40001)

## EUROPEAN SEARCH REPORT

Application Number  
EP 98 30 9554

| DOCUMENTS CONSIDERED TO BE RELEVANT  |   |  |  |
|--|---|--|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim  | CLASSIFICATION OF THE APPLICATION (Int.Cl.8) |
| A  | <p>O'BROCHTA D A ET AL: "TRANSPOSABLE ELEMENTS AND GENE TRANSFORMATION IN NON-DROSOPHILID INSECTS"<br/> INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD, GB,<br/> vol. 26, no. 8/09,<br/> September 1996 (1996-09), pages 739-753,<br/> XP000944507<br/> ISSN: 0965-1748<br/> * the whole document *</p> <p style="text-align: center;">-----</p> |  |  |
|  |   |  | TECHNICAL FIELDS SEARCHED (Int.Cl.6)         |
|  |   |  |  |
| The present search report has been drawn up for all claims   |   |  |  |
| Place of search  | Date of completion of the search  | Examiner   |  |
| THE HAGUE  | 23 July 2001  | Schmitz, T   |  |
| CATEGORY OF CITED DOCUMENTS  |   | <p>T : theory or principle underlying the invention<br/> E : earlier patent document, but published on, or after the filing date<br/> O : document cited in the application<br/> I : document cited for other reasons</p> <p>.....<br/> &amp; : member of the same patent family, corresponding document</p> |  |
| <p>X : particularly relevant if taken alone<br/> Y : particularly relevant if combined with another document of the same category<br/> A : technological background<br/> O : non-written disclosure<br/> P : intermediate document</p> |   |  |  |

